Efficacy of salmeterol 50 μg and fluticasone 250 μg combination therapy for the treatment of high altitude cough by Lohani, Ashish
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dissertation  
zum Erwerb des Doctor of Philosophy (Ph.D.) 
an der Medizinischen Fakultät der 
Ludwig-Maximilians-Universität zu München 
 
Doctoral Thesis for the awarding of a Doctor of Philosophy (Ph.D.) 
at the Medical Faculty of 
Ludwig-Maximilians-Universität, Munich 
 
vorgelegt von 
submitted by 
 
____________________________________ 
 
aus (Geburtsort) 
born in (place of birth) 
 
____________________________________ 
 
am (Tag an dem die Dissertation abgeschlossen wurde) 
submitted on (day of finalization of the thesis) 
 
__________________ 
 
 
 
Supervisors LMU:  
Habilitated Supervisor 
Direct Supervisor 
3rd LMU Supervisor 
4th LMU Supervisor 
 
Supervisor External: 
Local Supervisor 
___________________________________________ 
___________________________________________ 
___________________________________________ 
___________________________________________ 
 
 
___________________________________________ 
 
 
 
  
Reviewing Experts:   
1st Reviewer 
2nd Reviewer 
___________________________________________ 
___________________________________________ 
 
 
Dean: 
 
Prof. Dr. Dr. h. c. M. Reiser, FACR, FRCR 
  
Date of Oral Defence:  ___________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

- 1 - 
 
 
 
 
 
 
 
 
 
 
Efficacy of salmeterol 50 μg and fluticasone 250 μg combination therapy for the 
treatment of high altitude cough: A randomized controlled trial at Everest base 
camp  
  
- 2 - 
 
Abstract 
High altitude cough (HAC) is a common problem among climbers and 
sojourners to mountains. There is still no evidence-based treatment for this 
condition, likely because the very pathophysiology of the condition is not 
precisely known. We studied the efficacy of salmeterol 50 mcg and fluticasone 
250 mcg combination, one puff twice a day, in the treatment of HAC through a 
double-blind, placebo-controlled, randomized controlled trial.   
At Everest Base Camp (EBC), we enrolled 52 otherwise healthy individuals 
with HAC seeking treatment at the EverestER, a Himalayan Rescue Association 
Medical Clinic, during climbing season 2010/2011 and randomized to receive 
either salmeterol/fluticasone combination or placebo using rotahalers. The 
diagnosis was one of exclusion after completion of a self-administered 
questionnaire and physician examination. 
Forty two participants completed the trial, eighteen in treatment arm and 24 in 
placebo. Self-reported improvement of cough, Quality of Life assessment by a 
modified Leicester Cough Questionnaire (MLCQ) and clinical data were 
collected for analysis. Improvement of cough was assessed by Fisher exact test, 
MLCQ score and clinical parameters using Mann Whitney U test and Wilcoxon 
signed rank test. Analysis showed that combination treatment was not more 
effective than placebo in decreasing the severity of cough (P= 0.645). The odds 
ratio of significant improvement under treatment was 0.87 (95% CI 0.25-3.05). 
Mean MLCQ Score was 13.54±3.08 at baseline and 16.34±3.28 at follow up (P< 
0.001). The difference was larger for the placebo arm (P<0.001) than the 
treatment arm.  Improvement in cough and MLCQ score correlated with some 
symptoms and their severity at follow up. 
We concluded that inhaled salmeterol/fluticasone combination treatment 
through a rotahaler is not effective in treatment of the high altitude cough in 
EBC.  
Key Words  
(High altitude cough, Randomized controlled trial, Everest base camp, modified Leicester 
cough questionnaire) 
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Abstract 
High altitude cough (HAC) is a common problem among climbers and 
sojourners to mountains. There is still no evidence-based treatment for this 
condition, likely because the very pathophysiology of the condition is not 
precisely known. We studied the efficacy of salmeterol 50 mcg and fluticasone 
250 mcg combination, one puff twice a day, in the treatment of HAC through a 
double-blind, placebo-controlled, randomized controlled trial.   
At Everest Base Camp (EBC), we enrolled 52 otherwise healthy individuals 
with HAC seeking treatment at the EverestER, a Himalayan Rescue Association 
Medical Clinic, during climbing season 2010/2011 and randomized to receive 
either salmeterol/fluticasone combination or placebo using rotahalers. The 
diagnosis was one of exclusion after completion of a self-administered 
questionnaire and physician examination. 
Forty two participants completed the trial, eighteen in treatment arm and 24 in 
placebo. Self-reported improvement of cough, Quality of Life assessment by a 
modified Leicester Cough Questionnaire (MLCQ) and clinical data were 
collected for analysis. Improvement of cough was assessed by Fisher exact test, 
MLCQ score and clinical parameters using Mann Whitney U test and Wilcoxon 
signed rank test. Analysis showed that combination treatment was not more 
effective than placebo in decreasing the severity of cough (P= 0.645). The odds 
ratio of significant improvement under treatment was 0.87 (95% CI 0.25-3.05). 
Mean MLCQ Score was 13.54±3.08 at baseline and 16.34±3.28 at follow up (P< 
0.001). The difference was larger for the placebo arm (P<0.001) than the 
treatment arm.  Improvement in cough and MLCQ score correlated with some 
symptoms and their severity at follow up. 
We concluded that inhaled salmeterol/fluticasone combination treatment 
through a rotahaler is not effective in treatment of the high altitude cough in 
EBC.  
Key Words  
(High altitude cough, Randomized controlled trial, Everest base camp, modified Leicester 
cough questionnaire) 
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1. Introduction 
1.1. Cough 
Cough is a voluntary or reflexive explosive expiration that provides a 
normal protective mechanism for clearing the tracheobronchial tree of 
secretions and foreign material. It occurs as a consequence of aspiration, 
the inhalation of particulate matter, pathogens, accumulated secretions, 
postnasal drip, inflammation, and mediators associated with inflammation 
[1]. It is the most common symptom for which primary health care is 
sought for [2]. Persistent cough, in absence of other respiratory symptoms 
account for 10-30% of referrals to pulmonary specialists [3]. 
Cough commonly presents as a symptom of a disease of the respiratory 
tract or otherwise and rarely can present as the sole symptom. 
Symptomatic cough is divided into acute, sub-acute and chronic for 
diagnosis and management. Acute cough lasts less than 3 weeks and is 
commonly due to a respiratory infection, aspiration or noxious chemical 
or smoke inhalation. Sub-acute cough lasts 3-8 weeks and is commonly 
due to residual tracheo-bronchitis and bronchial hyper-responsiveness due 
to specific infections such as Mycoplasma pneumonia and Bordetella 
pertussis. It is usually a post-infective tussive syndrome. Sub-acute cough 
can also be caused by non-infectious factors such as gastro-esophageal 
reflux, aspiration, bronchial asthma and subclinical heart failure with fluid 
overload [4]. Chronic cough lasts more than 8 weeks and is caused by 
wide range of cardiopulmonary diseases. Cough variant asthma, gastro-
esophageal reflux disease, nasopharyngeal drainage (upper airway cough 
syndrome or the postnasal drip syndrome) and use of drugs are most 
common causes of chronic cough in absence of x-ray changes in the lungs 
[2, 3]. 
Cough is a clue to the presence of respiratory disease. However, excess 
cough may lead to complications. Patients with excessive cough may also 
suffer from emesis, muscular pain, syncope, rib fractures, aggravation of 
abdominal and inguinal hernias and urinary incontinence [3].  
Cough affects not only the physical but also the psychological and social 
facets of daily life in patients. Such effect can be measured by disease 
specific questionnaires which assess the overall quality of life. Quality of 
life in patients with cough is decreased significantly and can be measured 
- 10 - 
 
with cough specific quality of life questionnaires [5, 6]. Some cough 
specific questionnaires that have been validated are the Leicester Cough 
Questionnaire (LCQ) and the Cough Quality of Life Questionnaire 
(CQLQ) [5-7]. 
Even when cough is present as a troublesome symptom, is not always 
easy to determine the cause of cough. It is recommended to treat cough 
with respect to its etiology, type and severity of cough. Whenever 
possible, treatment of cough should be the therapy of underlying disease. 
On cases when a cause is not found, trial of an inhaled steroid, an inhaled 
beta-agonist or an inhaled anticholinergic agent is recommended. Only in 
severe cases of irritative and non-productive cough, suppression with a 
narcotic or a non-narcotic antitussive agent is recommended [2].  
Acute, sub-acute and chronic cough should be investigated and etiology 
determined before treatment. The term unexplained cough is used for 
cough for which etiology is not yet known [2].  
1.2. High Altitude Cough (HAC) 
High Altitude 
High altitude is defined by altitudes higher than 2500 meters and exposure 
of travelling individuals to hypobaric hypoxia. At 2500-3500 meters, 
acute exposure can cause decreased performance and change in sleep 
quality [8, 9]. Very high altitude is taken to be from 3500-5800 meters 
(3500-5500 meters taken by some authors [10]) and is characterized by 
fall in oxygen saturation below 90%  with common altitude illness and 
marked hypoxemia during sleep and exercise [9]. Above 5800 meters 
altitude (5500 meters according to some authors [10]), survival cannot be 
maintained permanently and there is progressive physiological 
deterioration with marked hypoxemia at rest [9]. 
Approximately 30 million western state visitors sleep at altitudes 2000 
meters and reach maximum altitudes of 3500 meters or higher each year. 
In the Everest region, 15,000 visitors each year sleep at altitudes 3000-
5200 meters [10]. All these visitors start to feel a host of changes in their 
bodies by being at altitude. Because of the progressive decreases in partial 
pressure of oxygen in the air, hypoxia develops. This hypobaric hypoxia 
initiates other related changes such as decrease in exercise capacity, 
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disturbances in sleep, various neuropsychological changes, and other 
effects of low temperatures and high ultraviolet light penetration [9, 10]. 
If human physiology does not adapt to the changing needs of the altitude, 
people suffer from various illnesses. These illnesses are called altitude 
illnesses and are primarily related to the failure of so called 
acclimatization, a process of temporary adaptation in the high altitude 
environment[8].  
Acclimatization is a complex series of physiologic adjustments that 
improve the oxygen delivery at the cellular level and improving the 
tolerance of tissues to hypoxia [10]. Acclimatization occurs over a short 
period of time. When these changes occur over decades to generations and 
confer advantages for life at high altitude, the process is termed 'altitude 
adaptation'. The main changes seen in the body physiology during 
acclimatization are hyperventilation, increase in red cell mass, 
redistribution of blood flow in the body, hemoconcentration and diuresis. 
Above very high altitudes exists the zone of high altitude deterioration 
with progressive weight loss, worsening appetite, poor sleep, and 
increased lethargy [9].  
Failure to acclimatize at high altitude may manifest in altitude sicknesses. 
The most common of these sicknesses in the acute mountain sickness 
(AMS) which is a symptom complex of headache, gastrointestinal upset, 
sleep disturbance, fatigue, and dizziness in varying degrees. Severe AMS 
can progress to life-threatening high altitude cerebral edema (HACE), 
where worsening of all the signs of AMS occurs along with neurological 
impairment visible as ataxia and altered mental status [9, 10]. Another 
life-threatening disease high altitude pulmonary edema (HAPE) occurs at 
altitude is characterized by profound dyspnea, fatigue and cough with or 
without symptoms of AMS and HACE [9]. Apart from these classical 
altitude-related diseases, there are other conditions and diseases either 
exacerbated at altitude or caused by being at altitude. Among others, a 
common problem at sea level and low altitude regions of the world, 
cough, is also a common problem at high altitude. 
Cough at high altitude 
Dry, hacking cough is a common problem at high altitude[11]. Chronic 
cough is almost universal in persons spending more than few days at 
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extreme altitude [12-14]. Climbing and expedition journals to high and 
extreme altitudes are seldom complete without the mention of HAC. 
HAC is also called the Khumbu cough after the famous Khumbu icefall at 
the base of Mt. Everest. Similar cough is also seen in other high altitude 
destinations around the world and can be described as high altitude 
bronchitis.  
Causes of HAC 
Exact pathophysiology of HAC has not been described though there are 
numerous hypotheses regarding its causation [9, 10]. 
At altitude, hypoxia lowers cough threshold [12, 15, 16]. Initially, in 
setting of hypoxia, cold and dry air of altitude was thought to cause HAC 
[10, 17]. Operation Everest III, a hypobaric chamber study, demonstrated 
an increase in cough frequency and cough receptor sensitivity with 
hypobaric hypoxia in a temperature and humidity controlled environment 
[18]. 
In a hypoxic environment, human respiratory physiology adapts 
depending on the level of hypoxia. Hyperventilation is an early 
physiological change in response to hypoxia. During acclimatization to 
high altitude, minute ventilation increases [19] resulting in increased 
water loss from the respiratory tract mucosa [20]. Further, the respiratory 
water loss is increased by the effect of exercise and hyperventilation [21, 
22]. Loss of water from respiratory tract due to hyperventilation and/or 
exercise at altitude causes desiccation of the airway. Drying of airways 
can result in symptomatic cough[17]. 
Hypocapnia ensuing from hyperventilation at altitude is also a potent 
broncho-constrictor. At high altitude, both hypoxia and hypocapnia are 
broncho-constrictors [23]. Hyperventilation induced bronchoconstriction 
is also associated with epithelial cell damage, and release of biochemical 
mediators in humans [20]. Bronchoconstriction can also be directly 
caused by exercise even in healthy persons [24].  It is also a chief feature 
of asthma. Degree of bronchoconstriction is correlated with cough in 
healthy as well as asthmatic subjects [25]. At high altitude, 
bronchoconstriction due to various causes can be a cause for HAC.  
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Hypoxic pulmonary vasoconstriction (HPV) causes pulmonary artery 
pressures to rise. At high altitude, this rise in pulmonary artery pressure 
causes increased micro-vascular hydrostatic pressure at the pulmonary 
capillary bed. On sufficient rise of the pressure, stress failure of the 
vascular endothelium causes the leakage of fluid to pulmonary 
interstitium and then to alveoli causing high altitude pulmonary edema 
(HAPE) [26, 27]. Impaired trans-epithelial clearance of sodium and water 
is thought to play a part in the development of edema, other supposed 
mechanisms contributing include altitude related endothelial dysfunction 
and impaired release of nitric oxide, exercise and cold related rise in 
pulmonary vascular pressure, hypoxia related increased sympathetic drive 
and increased vascular permeability secondary to infections and 
inflammation [28]. This edema occurs in 3 stages, starting with interstitial 
edema, leading to alveolar wall edema and finally alveolar flooding. One 
of the symptoms of HAPE is cough and occurs in up to 50% of the 
patients suffering with HAPE [29]. Though the relation of cough to HAPE 
is clear, patients with HAC do not suffer from frank HAPE. But it is still 
not clear whether sub-clinical HAPE, probably in the interstitial phase of 
edema, can lead to cough. Work from cardiogenic pulmonary edema 
points to the role of broncho-pulmonary C-fibers in causing tachypnea 
and dyspnea, but cough is not a predominant symptom. In light of debated 
role of C-fibers in cough production, there could be other receptors 
stimulated by the sub-clinical edema fluid, namely rapidly adapting 
receptors (RARs), as shown in rabbits[16].  Though the role of RARs is 
also debated in cough [30], it is thought to provoke cough response from 
mechanical stimuli [31], which here is the sub-clinical pulmonary edema 
of high altitude. 
Another factor at high altitude related to cough may be infections and 
post-infectious inflammation of the respiratory tract. In hypoxic 
conditions, we are prone to infections [32]. Often minor infections in high 
altitude areas might go undiagnosed since these areas are not always well 
equipped diagnostically. There are reports of green, purulent sputum 
associated with HAC but the common antibiotics do not seem to work 
[33]. In spite of this, there is still a chance that the cough could be an 
undiagnosed viral or bacterial condition that does not respond to the usual 
antibiotics recommended.  
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90% of all chronic cough is diagnosed to be caused by post-nasal drip 
syndrome, asthma, gastro-esophageal reflux disease or chronic bronchitis 
[34].  These are also the most frequent non-infectious causes of sub-acute 
cough that has not yet passed the 8 week mark [4, 35].  
Postnasal drip syndrome, or the upper airway cough syndrome, results 
from a multiplicity of rhino-sinus conditions, among which are allergic 
and non-allergic rhinitis, infectious and post-infectious rhinitis and 
sinusitis, rhinitis due to physical or chemical irritation and other forms of 
rhino-sinusitis [35]. Cold air, change in barometric pressure, temperature 
and humidity can cause a non-allergic vasomotor rhinitis [36]. High 
altitude, also a cold environment with hypobaria and decreased humidity, 
may cause rhinitis and post-nasal drip.  
Gastro-esophageal reflux disease is commonly associated condition with 
the development of sub-acute and chronic cough. GERD as a cause for 
chronic cough is reported as 5-41% in different studies[37]. This disorder 
can cause cough by different mechanisms, irritation of upper airways, 
lower airways by micro- or macro-aspiration or stimulation of 
esophageal-bronchial cough reflex [37].  At high altitude, prevalence of 
gastro-esophageal reflux disease has been found to be high [38].  
Both atopic and non-atopic asthma benefit from being at altitude [39, 40] 
but exercise induced bronchoconstriction has been reported in ski-
mountaineers [41]. Exercise in a cold environment increases exercise-
induced bronchoconstriction [42]. High altitude represents an 
environment of physiological exertion and HAC could as well be a 
manifestation of the bronchoconstriction due to the time spent there. 
Cough reflex and changes at high altitude 
Cough is a complex reflex; though it is a protective mechanism, there are 
cortical influences on it. There is no evidence seen for a cough center in 
the brain, and cough is brought about by the regulation of breathing 
pattern by the respiratory center. Cough is under voluntary control, but is 
not inhibited in anaesthetized subjects with respiratory depression and is 
suppressed by antitussive drugs with minimal depression of respiration 
[31]. These relations have not been well understood. 
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Cough originates from the sites innervated by vagus nerve, including ear, 
respiratory tract and abdomen. In the respiratory tree, in man, cough 
cannot be elicited from bronchiolar and alveolar irritation. The major 
afferent stimulus for cough in man thus is from larynx to the segmental 
bronchi. In man, additionally, larynx is thought not to be the important 
tussigenic zone but animal studies have shown extremely 
mechanosensitive receptors in larynx and trachea that can be related to 
persistent dry cough resulting from inflammations. In bronchial tree, the 
receptors are more chemosensitive but repeated exposures to these 
chemical stimuli cause accommodation in these receptors. 
These receptors can be one of the many possible present in the airways. 
Rapidly adapting and slow adapting receptors are myelinated Aδ and Aα 
fibers, while C-fibers are non-myelinated nerve fibers [31].  The so called 
'cough receptors' have been proven to exist in guinea pig models and are 
absent in animal species that do not cough [43].The roles of rapidly 
adapting receptors (RARs) and C-fiber receptors present in the airways 
have been debated in relation to cough [30, 31, 43]. The existence of a 
separate 'cough receptor' that responds exquisitely to mechanical or acid 
stimuli has been shown in the laryngeal, tracheal and bronchial mucosa 
[30, 43].   
Stimuli from these receptors are relayed via the vagus nerve to the nucleus 
tractus solitarius. The central mechanisms of integration of these stimuli 
and the corresponding brainstem response is still not completely 
understood [43].The cough response is a motor response, relayed through 
vagal and glossopharyngeal efferent nerves to the laryngeal, thoracic and 
abdominal muscles for a coordinated initiation of cough. Various areas in 
the respiratory control center adjust the different patterns of cough 
discharge [44].   
In case of high altitude, a global depression of cerebral function is present 
due to hypoxia. Prolonged exposure to hypoxia decreases cough reflex 
[45], but exposure to hypoxia decreases cough threshold to citric acid also 
[18]. We do not know how individual types of receptors are affected at 
altitude. RARs and C-fibers respond to foreign bodies, irritants in the 
respiratory tract, pulmonary edema and pulmonary congestion among 
other causes, though the responses vary considerably between the 
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receptors [31]. The 'cough receptors' on the other hand primarily respond 
to mechanical stimuli and acid [30]. Though sub-clinical HAPE may act 
through RARs, or C-fibers, presence of other pathologies such as GERD 
and PND could cough from higher zones in the respiratory tract by 
stimulating the 'cough receptors' in larynx, trachea and extra-pulmonary 
bronchi. Dry, desiccated airway could provoke cough due to minor 
mechanical stimuli through 'cough receptors' too. More work is required 
to understand the pathophysiology of HAC and to confirm the role of 
these receptors. This can help treatment of HAC by providing evidence 
for receptor-specific therapy which then can be studied. 
1.3. Problem statement 
It is difficult to really provide numbers on how many people each year 
suffer from HAC because of the difficulty and remoteness of the 
expeditions. Data obtained are generally from small teams and overall 
situation might be somewhat different than portrayed. Also, most studies 
focus in the trekker, non-Nepalese population for data, there being a lack 
of proper data on HAC in the Nepalese climbers. Overall prevalence of 
cough at high altitude is not available. In many instances, distinctions are 
not made between various types of cough, and the numbers of pharyngitis 
or bronchitis are reported. In other high altitude areas of the world, in 
South America, high altitude bronchitis is reported to be a common cause 
of morbidity among climbers.  
In Everest region of Nepal, prevalence of HAC has been reported in 
literature to be 12%[46] to 42%[11] depending on the resource consulted. 
At EverestER medical clinic at 5300 meters, HAC has been a leading 
cause for seeking medical care for last 10 years[47]. There are still at EBC 
a lot of climbers, especially Sherpas, who do not turn up at the clinic even 
though they have HAC. We also do not have the data on trekker 
population who reach very high altitudes of up to 5500 meters in the 
Everest region of Nepal and number in about 15,000 per year only in this 
area [10]. 
In addition to this, severe HAC results in failed expeditions. This is a big 
economic burden for the climbers. On an average, a non-Nepalese climber 
pays a total of 40,000$ to 100,000$ for climbing once at peak season at 
Mt Everest. Of this cost, 11,000$ is the cost of the permit to be paid to the 
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government of Nepal to climb, the rest depends on the level of logistics 
and support an expedition team provides [48]. For a Nepalese Sherpa, this 
cost is 75,000 Nepali Rupees during the spring season, with a provision 
for waiving from the government. The cost for a full set of good quality 
equipment for summiting Mount Everest is calculated to be around 
8,000$. Rest of the cost depends on the quality of individual expedition 
base camps and the quality of guides available for the climbers [48]. 
Severe HAC at basecamp or broken rib due to HAC causes failed 
expeditions and loss of the thousands of dollars per individual climber. 
For a Nepalese Sherpa, inability to climb further due to HAC costs the 
aforementioned costs of permit and equipment as well as the loss of salary 
and bonus totaling in a best case scenario from 2,000$ to 6,000$[49] if 
they had stayed healthy and completed their climb of the summit. 
1.4. A review of treatment options in HAC 
HAC develops typically as a severe, paroxysmal hacking cough, most 
commonly non-productive, but with occasional patient complaining 
productive nature. The cough typically gets worse with climbing higher 
into the mountain and gets better on climbing down to lower altitudes, 
which is the only way for severe cough patients to bet any form of 
improvement. Even after descent, the HAC persists typically for more 
than 6-8 weeks, thus falling into the category of sub-acute or chronic 
cough. At EverestER, altitude physicians have experienced HAC patients 
with intercostal muscle strains, probable rib fractures (absence of x-ray 
facilities at EBC for confirmation), blood streaked phlegm in occasional 
patient and a highly affected quality of life, not to mention loss of sleep 
for self and others during night time paroxysms of coughing. 
As such, over the years, an effective treatment for HAC has remained 
elusive. High altitude physicians have used many forms of treatment in 
HAC. The forms of treatment tried generally fall under the categories 
general measures that are not specific to cough; use of antitussive agents; 
use of antibiotics; and treatment of conditions potentially causing cough. 
General measures and over the counter preparations  
Use of masks, balaclavas or silk scarfs while climbing to retain the 
respiratory moisture and maintenance of hydration are advocated as 
general measures [9, 10]. Forced hydration is recommended to help 
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maintain the water balance, but it is not a treatment targeted specifically 
to respiratory mucosa. Use of masks or to retain respiratory moisture is 
also recommended to all climbers at altitude and is mostly for prevention. 
Symptomatic treatment can be tried with steam inhalation, hard candies, 
throat lozenges, different cough syrups and preparations [9]; though they 
have not been found effective in HAC. Treatment with over the counter 
preparations like guaiaphenesin, mucolytics, anti-histamine decongestant 
combination preparations, antihistamines alone and over the counter 
bronchodilator have not shown quality evidence in treatment of cough  
and have unknown efficacy in treatment of HAC [50]. 
Oxygen therapy to reverse hypoxia, thereby reversing the physiological 
changes can be hypothesized to work in HAC. Oxygen is the first form of 
therapy for severe and life threatening altitude illnesses, high altitude 
pulmonary and cerebral edema [51]. But HAC is not associated with 
desaturation and patients generally do worse after inhaling oxygen from 
canisters as the bottled oxygen lacks moisture and causes further drying of 
the respiratory tract.  
Antibiotic treatment in HAC 
Presence of purulent sputum with HAC leads to frequent trial of 
antibiotics to treat a possible infection. From personal experiences, for 
treatment of respiratory infections in Nepalese mountains trekkers are 
usually prescribed azithromycin from their general practitioners to be 
used during any doubts of infections in settings where health care is not 
available easily. It is not unusual to find a patient with cough self-treated 
with antibiotic regimen multiple times, to turn up at EverestER with the 
cough still not treated and with a spectrum of added complications due to 
side effects of the drugs used. In absence of other signs of infection; high 
temperature, respiratory examination findings suggestive of infection, 
antibiotics are not recommended in HAC [10].  
Antitussive treatment 
Codeine is a centrally acting opioid antitussive commonly used in 
treatment of cough. It is used in severe cases of HAC when other 
measures do not bring about an improvement in cough severity, often 
combined with descent of patient to a lower altitude. Two studies, one of 
them a double-blinded, stratified, placebo-controlled, parallel group 
research failed to show a difference between codeine and placebo in the 
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treatment of cough associated with acute upper respiratory tract 
infections[4]. Non-opioid antitussive, like dextromethorphan, are thought 
to have limited efficacy (less than 20% cough suppression) also have 
shown mixed results in experimental studies [52].  Overall, centrally 
acting antitussives have shown a marginally superior benefit over placebo 
in improving cough status in patients. 
Though antitussives might improve cough, they are not without their 
costs. Codeine causes respiratory depression has been prohibited to be 
used in children under 12 years and in patients above 12 with respiratory 
function impairment [53]. It also causes drowsiness (>10%), paradoxical 
nervous system stimulation, dizziness and confusion in up to 10 % 
patients taking the drug. Dextromethorphan also causes dizziness, 
drowsiness and confusion as common side effects. A climber in hypoxic 
environment with a physiological respiratory functional impairment is put 
in a higher risk when s/he has to make decisions at every step of the climb 
that are important to safety of self and others on the mountain. This makes 
it imperative, especially in a high risk environment of high altitude, to 
find safer alternatives in treatment of HAC. 
Treatment of causal factor/ related condition 
Problem with specific treatment for HAC is that the pathophysiology is 
not established.  Literature review has suggested sub-clinical HAPE, 
GERD, postnasal drip syndrome, bronchoconstriction and asthma and 
post-infectious cough as potentially treatable conditions probably 
resulting in HAC. 
Sub-clinical HAPE as a pathophysiological basis for HAC would imply 
HAPE prevention treatment could have a role in its treatment. Salmeterol, 
a beta-agonist, is used for HAPE prevention for its action in the 
pulmonary Na+ channels that prevents the stress failure of the pulmonary 
blood- alveolar barrier and helps to keep fluid out of the alveoli [54]. 
Dexamethasone, by modifying various physiological processes has also 
been found to prevent increase in pulmonary artery pressure, thereby 
significantly decreasing the precipitation of HAPE in HAPE-susceptible 
subjects [55]. Fluticasone, though not studied specifically in HAPE, is 
also a steroid and could have similar beneficial effects in HAPE 
prevention.  
Hyperventilation/hypocapnia related bronchoconstriction are reversed by 
beta-agonists [56]. Considering HAC to be an otherwise undetected form 
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of exercise-induced broncho-constriction [41] or a form of previously 
unidentified cold or exercise induced asthma, a combination treatment of 
a beta-agonist and a steroid would relieve the broncho-constriction and 
associated inflammation, thereby improving HAC. 
Post-infectious cough is common cause of sub-acute coughs and occur 
after bacterial or viral upper and lower respiratory tract infections. 
Though the cause of infection is no more, inflammation of the airway and 
subsequent bronchoconstriction are responsible for cough in this scenario. 
For this reason, anti-inflammatory and bronchodilator drugs would be in a 
position to reverse cough. Steroid [57] and beta-agonist drugs are in pole 
position to reverse these processes. 
Since vasomotor rhinitis is common in cold environments and as such in 
very high altitudes, reversal of rhinitis or its prevention could be a way to 
treat HAC. Anti-histamines and steroids are used commonly to treat 
VMR. Studies with fluticasone have shown that it is superior to placebo in 
treatment of VMR [58]. 
Gastro-esophageal reflux disease and its extra-esophageal manifestations 
are treatable causes of cough. Proton-pump inhibitors are the most 
effective form of medical treatment for GERD [59]. Treatment of GERD 
would rectify the effect of micro and macro aspirations as well as laryngo-
pharyngeal reflux and thus improve or treat cough.  
A combination treatment of steroid and beta agonist was studied in 
patients with persistent dry cough and found effective [60]. Steroids are 
used in treatment in low altitude for unexplained, idiopathic chronic 
cough. Fluticasone has been found effective in reduction of cough in non-
smoking previously healthy adults [61]. 
2. Rationale and Objectives 
2.1. Rationale 
Anecdotally, high altitude physicians working at EverestER medical 
clinic and other high altitude health posts around the world have found the 
combination of steroids and beta-agonists to be effective in treatment of 
HAC [47]. Steroid, in this case fluticasone, can be argued to prevent 
HAPE, stop inflammatory processes related to asthma and infection, treat 
vasomotor rhinitis and PND. Beta-agonist, here salmeterol, would also 
prevent HAPE and reverse bronchoconstriction. Together, a combination 
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treatment of salmeterol/fluticasone can be argued to improve significantly 
or treat significantly higher number of patients with HAC in comparison 
to placebo treatment. If the combination treatment of fluticasone and 
salmeterol is found effective in treating HAC, it would simultaneously 
rule out the role of dry air, respiratory loss of water, active infection and 
gastro-esophageal reflux disease. 
On the probable scenario that the drug combination has a significantly 
higher efficacy in improving HAC, then we could make a case for the 
abovementioned conditions. A follow up research with individual drugs 
would reveal if there is any difference between the individual components 
that are quite different in the pharmacological activity. Should there be a 
difference, a theory on pathophysiology of HAC can be generated and 
tested based on such results. 
2.2.  Objectives 
The principle objective of this study was to examine whether anecdotally 
successful treatment regimen of salmeterol/fluticasone is better than 
placebo in improving self-reported cough status in HAC. 
The secondary objectives of this study were: 
1. To assess quality of life in patients of HAC with modified Leicester cough 
questionnaire (MLCQ) and to compare the change in the quality of life 
between treatment arms. 
2. To describe associated clinical characteristics and pulmonary functions of 
HAC and compare between arms the effects of treatment on these 
variables. Pulse rate (HR), oxygen saturation (SpO2), systolic and 
diastolic blood pressure (SBP and DBP), peak expiratory flow (PEF) and 
forced expiratory volume at first second (FEV1) were to be assessed. 
3. To assess role of exercise in HAC. 
4. To describe symptoms related to HAC in terms of severity and find a 
relation between symptom severity and improvement in cough. 
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3. Methods 
3.1. Design and patients 
The study was a single-center, randomized, double-blind, placebo- 
controlled trial to test the efficacy of salmeterol 50 mcg and fluticasone 
250 mcg combination, one puff twice a day regimen in the treatment of 
HAC. Rotahalers, simple dry powder inhaler devices, were used to deliver 
treatment combination or placebo. Enrollment took place in the months of 
March, April and May in 2010 and 2011 at the Everest base camp (EBC, 
5300 meters) in Nepal.  
Mountaineers, as they ascended to base camp, were made aware of the 
study by means of recruitment posters in the lodges that provided 
accommodation in the villages along the way to the Everest Base Camp 
and also by requests for volunteers at the daily altitude education talks 
given at the Himalayan Rescue Association post in Pheriche. Interested 
mountaineers were given adequate explanation regarding the study again 
by the EverestER doctors and asked if they would like to participate.  
Study staff ensured that participants did not meet any of the exclusion 
criteria. Participants who provided informed consent were assigned a 
study number and requested to fill out a baseline modified Leicester 
Cough Questionnaire (see attached).  They had their blood pressure, 
pulse, peak expiratory flow, FEV1, O2 saturation measured and lung and 
heart auscultation carried out. Participants then received pre-randomized 
numbered medication packages along with rotahalers with either 
combination of inhaled salmeterol 50 mcg and fluticasone 250 mcg or 
placebo. The medication packages were pre-randomized during 
production at the pharmaceutical company. The rotahalers had a 14 day 
twice-a-day dosing supply of drug capsules. The randomization numbers 
of the corresponding packages were noted.  
The rotahaler is a simple device (also called DPhaler) for dry powder 
inhalation, used together with drugs packaged in capsules, called 
rotacapsules or rotacaps. Rotahalers are simple to use with dry powder 
inhaler delivery mechanism. They are breath actuated, portable, small, 
without need for propellants and can be operated with less patient 
coordination [62]. The participants were given uniform training on the use 
of the rotahalers by the corresponding author and other study 
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administrators, all of whom were high altitude physicians involved in 
patient care at the EverestER.  
Between days 7-14, the subjects were re-assessed using the same 
parameters and the modified LCQ. Unused medication was collected and 
remaining pill count was noted for all participants. This was then disposed 
of according to local regulations.  
Two sealed master lists of the randomization code were held by the 
manufacturer, and an independent clinician at the Nepal International 
Clinic in Kathmandu. 
3.2. Inclusion and Exclusion criteria 
The inclusion criteria for the study subjects were otherwise healthy men 
or women; age 18-65 years; staying in EBC (5,350 meters) or higher for 2 
weeks before enrollment, suffering from HAC. Signed informed consent 
form was essential to participate in the study.  
Exclusion criteria were other diagnoses causing cough (e.g. probable viral 
or bacterial upper and lower respiratory tract infections, HAPE); 
unwillingness to comply with study treatment, contraindications for use of 
the drugs under study; use of beta-agonists, steroid inhalers, steroid nasal 
sprays or oral steroids use in the previous 2 weeks.  
3.3. Ethics Statement 
The study was conducted in accordance with the Declaration of Helsinki. 
We obtained ethical clearance from Nepal Health Research Council and 
Oxford Tropical Research Ethics Committee before the start of research. 
Ethical clearance from Ludwig Maximilian University was obtained 
during the PhD schedule of first author. Written informed consent was 
obtained from all participants at enrollment. The trial was duly registered 
at the international standard randomized clinical trial registry (ISRCTN: 
76835758). 
3.4. Case definition  
HAC was defined as persistent, sometimes paroxysmal cough of more 
than 1 day duration that disturbs sleep or daily activity or both at high 
altitude. It could be dry or productive but was not associated with fever, 
chills, shortness of breath or desaturation < 75 % at EBC (5300 m) and 
was diagnosed by high altitude physicians working at the EverestER.  
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For the diagnosis, clinical history and examination was completed by the 
physicians. During examination, auscultation of heart and lungs was 
carried out for all participants. Only participants with unremarkable 
findings on auscultation of heart and lungs along with the characters 
mentioned in the case definition were explained about the research 
procedure and invited to take a part in the study. 
3.5. Instruments  
3.5.1. Self-reported improvement in cough at follow-up 
The self-reported improvement in cough was assessed at follow up. The 
response reported was a Likert scale with 5 levels of improvement in 
cough. The levels were coded 1-5 respectively for 'No Improvement', 
'Improved a bit', 'Improved moderately', 'Improved greatly', and 
'Completely resolved, No cough!' 
Cough is a difficult entity to measure. As a symptom, it can be measured 
in various dimensions. Objective and subjective measures are both used in 
cough reporting. Cough counter devices and cough threshold testing are 
objective measures. Self-reported cough, visual analog scale and cough 
specific questionnaires are subjective measures [7] and are regularly used 
in researches of cough.  
3.5.2. Modified Leicester Cough Questionnaire (MLCQ)  
Leicester cough questionnaire (LCQ) is a valid, reliable tool to assess 
cough specific quality of life and is commonly used in cough research. 
LCQ was devised to assess quality of life in patients with cough. It has 
been validated across different settings and respiratory conditions for 
cough [5, 63]. The LCQ has 19 items belonging to the categories physical, 
psychological and social effects of cough in the patient under treatment or 
observation. Each category is defined as a domain. The physical domain 
has 8 questionnaire items, psychological domain has 7 questionnaire items 
and the social domain has 4 questionnaire items. The questionnaire is self-
reported by the patients. On completion of the questionnaire, score is 
calculated from the domains, and the domain scores are added to calculate 
the LCQ score, which gives the idea of the quality of life in a patient.  
Domain score= Total Domain Score/Number of items in the domain 
LCQ Score = Physical Domain Score + Psychological Domain Score + 
Social Domain Score 
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Thus the domain scores can range from 1-7 and the LCQ score can range 
from 3-21.  
LCQ was modified by experts in altitude medicine for use in the 
mountaineering population. Modified LCQ used 18 of 19 original items of 
the LCQ [5]. One item of the psychological domain was dropped and one 
question added to the physical domain. Modified Leicester cough 
questionnaire (MLCQ) contained 19 questions, each item a Likert scale 
item with possible scores from 1 to 7. 1 was the least quality of life and 7 
the best quality of life possible for each question. 
 MLCQ consisted of three domains viz. physical, psychological and social 
as the parent questionnaire. The physical domain consisted of 9 questions, 
psychological domain 6 questions and social domain 4 questions. 
Participants completed the Modified LCQ at baseline and follow up. On 
completion of the MLCQ, scores were calculated similar to the LCQ. 
Domain scores were calculated and added together to get the MLCQ 
score. 
3.5.3.  Relation of HAC to exercise 
HAC is still a cough of unexplained etiology. High altitude is an 
environment of constant hypoxic strain to human body and physiology. It 
is known that exercise can cause bronchoconstriction and cough in normal 
subjects [24]. It is not known whether exercise-induced 
bronchoconstriction plays a role in development of HAC. We explored 
the relation of HAC to exercise as 3 possibilities, a cough brought on by 
exercise, a cough made worse by exercise and a cough with no relation to 
exercise. The responses from participants were collected at baseline and 
follow up. 
3.5.4. Symptom severity checklist  
A 14 symptom checklist was developed by altitude medicine experts for 
use in this study to assess severity of symptoms of HAC. A 14 symptom 
checklist was developed by experienced altitude physicians to assess the 
presence and severity of various symptoms that might be associated with 
HAC, especially in the light of the unexplained pathophysiology of HAC. 
Symptoms assessed were related to the severity of cough or gastro-
esophageal reflux and postnasal drip.  
Symptoms related to cough severity 
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Symptoms ‘retching and vomiting while coughing’, ‘cough with eating’, 
‘cough with certain foods’, ‘cough while getting out of bed in the 
morning’, ‘cough brought on by speaking or singing’, ‘cough more while 
awake than asleep’  and ‘chest tightness or wheeze when coughing’ 
assessed direct impact of cough on daily life. Wheezing is a symptom of 
asthma. 
Symptoms related to gastro-esophageal reflux and postnasal drip 
These are hypothesized pathophysiological factors for HAC. The 
symptoms included ‘hoarseness’, ‘heartburn, indigestion or stomach acid’, 
‘tickle or lump in throat’, ‘strange taste in mouth’, ‘clearing throat’, ‘post 
nasal drip’. ‘Cough on lying down or bending over’ assessed cough 
severity as well as gastro-esophageal reflux symptom, but was pooled 
with the gastro-esophageal reflux symptomatology[64]. 
3.5.5. Clinical data 
Participants went through a medical examination at the EverestER, by 
high altitude physicians before being diagnosed as HAC. Lung and heart 
auscultation were performed while taking a note of basic clinical 
parameters. Pulse rate, blood pressure and oxygen saturation were 
recorded both at baseline and follow up. Pulse rate (HR) was measured in 
in beats per minute, oxygen saturation (SpO2) in percentage, systolic and 
diastolic blood pressure (SBP and DBP) in mmHg. The treatment regimen 
used in the study has effects on the general clinical parameters. 
Salmeterol, a beta-agonist, increases heart rate [65] which can be explored 
at post-treatment phase in contrast to placebo. Similarly, it also has effect 
in decreasing diastolic blood pressure [66, 67]. Salmeterol/fluticasone 
combination was shown in one study not to affect oxygen saturation after 
inhalation for up to 720 minutes in patients with chronic obstructive 
pulmonary disease (COPD) [68], whether same results will be seen at 
high altitude remains to be seen. 
High altitude brings about a decrease in FVC, increase in PEF and no 
change in FEV1 [23, 29, 69]. Salmeterol is an effective bronchodilator 
and improves FEV1 and PEF in asthmatics [70]. To measure the changes 
in the pulmonary function at altitude, PEF and FEV1 were chosen to be 
studied at baseline and follow up. Measurement of PEF and FEV1 would 
also reflect the degree of bronchoconstriction in the study arms at baseline 
and the difference brought by intervention at follow up. PEF was 
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measured in liters/second and FEV1 in liters using Microplus spirometer 
in 2010 and Jaeger Spiropro spirometer in 2011.  
3.5.6. Altitude of occurrence of HAC 
Altitude related cough, studied earlier by Mason, is thought generally to 
occur in two different forms. One type, occurring over 5000-6000 meters 
is hypothesized to be related with the sub-clinical HAPE and the second 
type, occurring below 5000 meters altitude hypothesized to be more 
commonly associated with airway mucosal trauma and infections [29]. 
We asked the participants to report at which altitude HAC occurred. The 
responses were reported in 6 altitude ranges; 1000-1999 meters, 2000-
2999 meters, 3000-3999 meters, 4000-4999 meters, 5000-5999 meters 
and 6000 meters or higher. The altitude of EBC fell in the third range of 
5000-5999 meters. 
3.5.7. Pill count 
28 rotahaler capsules were in each medication packaging the participants 
received at enrollment. A count of the remaining rotahaler capsules was 
recorded at follow up visit, as a proxy measure for compliance to 
treatment.  
3.5.8. Demographic Information 
We collected information on age, gender and nationality as well as type of 
expedition, time taken to reach very high altitude, time of acclimatization 
before enrollment, previous illnesses, current treatments and allergies. For 
better characterization of climbing population and understanding of 
possible background variables in relation to the development of HAC, 
these background variables were useful. 
- Month of arrival at EBC: Climbing season at Everest is just a small 
window from the end of April to end of May. Arrival earlier or later might 
influence level of acclimatization at 5300 meters at EBC. 
- Date of arrival and date of enrollment: These two dates would make it 
possible to calculate the time spent in the altitude of base camp or above, 
as a part of the inclusion/exclusion criteria. 
- Number of nights taken from Lukla to EBC: From Lukla at 2800 m to 
Everest base camp at 5300 meters, it is a 2500 meters vertical ascent. 
According to UIAA, the international union of mountaineering federation, 
the recommended daily vertical ascent to be travelled at high altitude is 
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300-500 meters, and every 900-1000 meters to be taken as an 
acclimatization day[71]. This would come about to be 11 days with 300 
meters/day calculation and 8 days with 500 meters/day calculation. Lesser 
number of days would point to incomplete acclimatization as well as 
higher levels of fatigue. 
It is not clear how this rule applies to the high altitude residents, the 
Nepalese population group reflected in this study, as their physiological 
changes are those reflecting adaptation to high altitude and not 
acclimatization. 
Association to the number of nights taken by a climber to reach EBC from 
Lukla might point out associations with the level of acclimatization 
profile and the development of HAC.  
- Independent climber or climber in a commercial expedition: Independent 
climbers are under much more physical stress during climbing, especially 
in Everest than their colleagues in a commercial expedition team. The 
independent climber carries all his loads to the higher camps and sets his 
own camps at high and extreme altitudes whereas in a commercial 
expedition, there is a group of helping climbers, mainly Sherpas in Nepal, 
who carry the loads to higher camps and set up camping spaces. Being an 
independent climber is a proxy to increased physical stress. In terms of 
Nepalese Sherpas, this rather would not apply as they all work for 
commercial expeditions. 
- Use of acetazolamide during trekking to EBC: Acetazolamide accelerates 
the process of acclimatization and is used for treatment of acute mountain 
sickness. Association to acetazolamide would associate HAC to 
acclimatization related disorders. 
- Breathlessness with HAC: Breathlessness is a common symptom at 
altitude after any form of exercise. But breathlessness disproportionate to 
the level of exercise is an early symptom for high altitude pulmonary 
edema. A paroxysm of HAC also could leave the patient breathless for 
minutes after coughing. Similarly, breathlessness could also be a part of 
ongoing lower respiratory tract infection or inflammation. So a high 
proportion of breathlessness reported during HAC would warrant further 
examination of the variable. 
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- Long-term illnesses: Probable participants with long term respiratory 
system disease directly causing cough were excluded from study.  
- Patient on any regular long term treatment: Patients on regular long term 
medicines that could give rise to or that could interfere with the 
assessment of HAC were screened by the question. Beta-agonists or 
steroid treatments fell under exclusion criteria. Similarly, ACE-inhibitors 
can be a cause for cough itself.  
- Presence of allergies: This variable was used to identify presence of 
allergies in patients with HAC. Presence of allergies in significant amount 
of participant points to its association with HAC which can be explored in 
future studies. Presence of allergies could be a pointer to a possible 
association between airway hypersensitivity and HAC. 
- Age: Mountaineering population is principally an adult population, mostly 
healthy and fit. But recent mountaineering demography points to the fact 
that older people are climbing mountains more. A possible difference 
between treatment arms could make the results biased.  
- Gender: Males outnumber females in climbing, but there is no data on 
whether HAC is affected by gender, and if there is any association, it 
might affect the end result in the study. 
- Nationality: Nepalese Sherpas are the local population of the Everest 
region and are in the mountain in a regular basis and have a genetically 
favorable propensity to function at high altitude. Similarly, having worked 
at the same environment for years, they could develop a different attitude 
to HAC, a disease that affects their functionality at high altitude but 
gradually diminishes and is cures after weeks or months of returning to 
their lower altitude of residence. This could bring about the differences in 
the MLCQ reporting compared to non-Nepalese nationals. 
Oxygen saturation, mean blood pressures and heart rate for a population 
adapted to live in high altitude is different to that of a non-resident of high 
altitude. Standard normal values for spirometry in Nepalese population 
are not established, but are decidedly much lower than the standard 
normal values for the European or American population. This could bring 
about a bias in the comparison of respiratory function measurements. 
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3.6. Outcome variables 
3.6.1. Primary and Secondary Outcomes 
Improvement in cough was the primary outcome of this study. Secondary 
outcome measures were MLCQ score for quality of life assessment, 
assessment of symptom checklist, HR, SpO2, SBP, DBP, mean arterial 
pressure (MAP), PEF and FEV1.  
3.6.2. Improvement in Cough 
Improvement in cough was primary outcome measure of this study; self- 
reported by participant at follow up visit in a 5 point scale (described in 
detail in 3.4.1). Improvement in cough was reported only at follow up. 
The outcome measure was reported and compared between treatment and 
placebo arms.  
The responses were grouped into dichotomous variable for analysis, with 
scale values 4 and 5 reflecting respectively greatly improved cough and 
completely resolved cough considered as significant improvement in 
cough. Scale values 1-3 (no improvement, improved a bit and improved 
moderately) were considered non-significant improvement in HAC. 
Inference of significant and non-significant outcome was determined in 
placebo and treatment arm of the study, and the results reported. 
Comparison between arms was done at follow up and any difference 
tested statistically. 
3.6.3. MLCQ score 
The domain scores were calculated as (sum of item scores/number of 
items in the domain) with a range 1-7. MLCQ score was calculated as the 
sum of domain scores (range 3-21) [5]. MLCQ score was calculated for 
both arms at two points of study, baseline and follow up. The change in 
MLCQ score from baseline to follow up was calculated and compared 
across treatment arms. The change in domain scores were also reported 
and compared between arms. For each domain, at baseline and at follow 
up, reporting and comparison between groups was done for each 
questionnaire item.  
Additionally, MLCQ scores were compared between Nepalese and non-
Nepalese respondents of the study to check the consistency of response 
across nationalities.  
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Cronbach’s alpha was calculated at baseline and at follow up as a 
reliability marker for the questionnaire. It is the statistical measure of 
internal consistency, it shows that all the items in a questionnaire like 
MLCQ are measuring the same thing and are correlated to each-other 
[72]. A measure of  “> .9 – Excellent, > .8 – Good, > .7 – Acceptable, > .6 
– Questionable, > .5 – Poor, and < .5 – Unacceptable” is generally 
regarded as the rule of thumb in Cronbach’s alpha values [73]. 
3.6.4.  Relation of HAC to exercise 
Frequency of relation of cough to exercise was explored at baseline and 
explained in the total population. Comparisons were made between 
treatment arms with and distribution explained also by nationality. At 
follow up, the distribution of frequencies was explained and placebo arm 
compared to treatment arm to explore any differences. 
3.6.5. Clinical variables 
Oxygen saturation (SpO2) was measured in percentage, systolic and 
diastolic blood pressure (SBP and DBP) in mmHg, peak expiratory flow 
(PEF) in liters/second and forced expiratory volume in 1 second (FEV1) 
in liters. The variables were reported for each arm and compared at 
baseline and follow up between the study arms. Change in the variables 
from baseline to follow up was calculated and compared between the 
treatment arms. 
3.6.6. Symptom severity checklist 
The symptom checklist was measured in a scale 0-5, 0 denoting no 
problem at all and 5 denoting severe problem with the listed symptom. All 
14 symptoms were explored for differences between study arms. 
Reporting of severity and comparison between arms was done at baseline 
and follow up. Additionally, change in severity from baseline levels was 
calculated for each symptom. The change was described across study 
arms and compared. The change in symptom severity was correlated with 
improvement in cough at follow up and change in MLCQ score in each 
arm at follow up. 
3.6.7. Compliance to treatment 
This was seen by looking at pill count on follow up. Patients were asked 
to return with the packaging of the rotahaler capsules and remainder were 
counted, noted and collected for disposal. At follow up, pill count was 
compared between treatment arms. 
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3.7. Power calculations and statistical analysis 
3.7.1. Power calculation:  
Power calculation for the study was done based on the primary endpoint 
“improvement of cough”. Fisher exact test was used to test the difference 
among study arms. The assumptions were made for 70% patients in 
treatment arm to have a “Significant Improvement of cough” and 20% in 
the placebo group for the same result. On completion of 2 years of study 
period in Everest base camp, a total of 52 patients could be enrolled, with 
valid response to the primary outcome question reported by 40 
participants at follow up. Power of 0.91 was reached during the study with 
18 participants in treatment arm and 22 in placebo arm for achieving type 
1 error probability rate 0.05 to prove significant difference between 
treatment and placebo groups. 
3.7.2. Statistical Analyses: 
Normally distributed values were presented as mean ± standard deviation 
(SD), non-normally distributed values as median, first and third quartile 
(Q1–Q3). Categorical data was presented as frequency and percentage. 
Fisher exact test and odd's ratio were used to investigate primary outcome 
'Improvement in Cough'. Mann-Whitney U test and Wilcoxon Signed 
Ranks test were used to investigate differences between placebo and 
treatment and between enrollment and follow up measurement values for 
MLCQ and clinical variables. Correlation of improvement in cough at 
follow up and change in MLCQ score with change in symptom severity at 
follow up analyzed with Spearman’s rank correlation co-efficient. 
All the data was analyzed with the help of SPSS 17.0 after initial 
documentation on paper. 
4. Results 
4.1. Characteristics of Participants 
52 subjects were recruited at the Everest Base Camp Clinic in 2010 and 
2011 April-May spring climbing seasons. Only 3 (5.77%) enrollees were 
independent climbers, the rest being associated with commercial 
expedition groups. 37 (71%) arrived in the base camp during the month of 
April, 12 (23.1%) in March and 1 (1.9%) in May during both years of the 
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study. There was no difference between treatment and placebo arms in 
terms of month of arrival to EBC (P= 0.858). 
46 (88.46%) males and 6 (11.54%) females were enrolled, 39 (75%) were 
Nepalese and 13 (25%) non-Nepalese. On comparing the placebo arm 
with the treatment arm, there was no difference in terms of gender (P= 1) 
and nationality (P= 1). 
42 were successfully followed up, 6 enrollees were lost to follow up and 4 
dropped out of the study. The general characteristics of the patients with 
HAC who were enrolled for the study are shown in the table 1. 
Table 4-1 Baseline characteristics of study participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age 
Mean age of the baseline population was 34.42±8.66 years. There was no 
difference between placebo and treatment group in mean age (Z= -0.248, 
P= 0.804). The Nepalese population was much younger (mean age 
32.39±5.78 years) in comparison to the non-Nepalese population (mean 
age 41.00± 12.88 years). The difference in age according to nationality 
Age (in years) 
 
34.42±8.66 
Sex 
Male 46 (88.46) 
Female 6 (11.54) 
No. of nights from Lukla to EBCa 
 
6.10±3.81 
With Allergies 
 
0(0) 
Drugs at the time of study 
 
10 (19.23) 
Using Acetazolamide 
 
1 (1.92) 
Chronic illness 
 
3 (5.77) 
Without Breathlessness 
 
31 (59.62) 
Pulse Rate (per minute) 
 
82.37±15.48 
Systolic BP (mmHg)b 
 
133.43±14.99 
Diastolic BP (mmHg)b 
 
86.20±12.51 
Mean Arterial Pressure (mmHg)b 
 
101.94±12.28 
SpO2 (%) 
 
83.06±3.84 
FEV1 (liters)b 
 
3.62±1.01 
PEF (liters/second) 
 
8.79±2.77 
Notes:  
Data are Mean±SD or n (%). EBC= Everest Base Camp, 
BP=Blood Pressure, mmHg= millimeters of mercury, SpO2= 
Oxygen Saturation, FEV1= Forced Expiratory Volume in 1st 
second, PEF= Peak Expiratory Flow. 
a N=41, b N=51 
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was significant (Z= -2.02, P= 0.043). Age was not different significantly 
in comparison of the male and female participants of the study.  
 
 
 
Figure 4-1: Flow diagram of HAC study 
Total Lost to Follow Up 10 
Total Follow Up Completion 
Placebo  
Total Followed Up 24 
Completed Questionnaire 22 
 
Treatment  
Total Followed Up 18 
Completed Questionnaire 18 
 
Clinical Examinationa and Enrollment 
Recruitment and Randomization (n=52) 
Placebo (n=28) Treatment (n=24) 
Total Lost to Follow Up 3 
Dropped Out 3 
Total Lost to Follow Up 3 
Dropped Out 1 
- 35 - 
 
 
Figure 4-2 Age distribution by nationality 
Nepalese climbers were significantly younger than non-Nepalese climbers (P= 0.043). 
Number of nights required to reach EBC 
The mean number of nights taken by the participants to reach the EBC 
was 6.10. The minimum was 2 and the maximum 17 nights. On analysis 
by nationality, there was a significant difference between Nepalese and 
non-Nepalese nationality in the number of nights required to reach EBC 
(Z= -4.073, P= 0.000), Nepalese participants needing on an average 
4.5±2.45 nights and non-Nepalese participants needing 10.45±3.45 nights 
to reach EBC. Participants from treatment arm in comparison to placebo 
arm took longer time to get to Everest Base Camp from Lukla, but the 
difference was not significant. 
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Figure 4-3 Number of nights taken by Nepalese and non-Nepalese climbers from Lukla to reach EBC 
Nepalese climbers took much less number of nights (P= 0.000). This exposes them to higher risks of altitude 
illness. 
Use of prescribed medication 
Ten out of the 52 participants were taking some form of treatment at 
baseline. Of the medications in use were non-steroidal anti-inflammatory 
drugs (celecoxib and paracetamol alone or as combination), glatiramer 
(copaxone) for multiple sclerosis, alendronate, metaxalone, levothyroxine, 
omeprazole, vitamin tablets, guaiafenesin and dextromethorphan. 
Guaiafenesin was taken as a pro re nata prescription by 1 participant and 
dextromethorphan by 1 participant. These anti-tussives were not in the 
exclusion criteria. On analysis by nationality, 3 Nepalese participants used 
prescribed medication, those being paracetamol, omeprazole and throat 
lozenges. Other medications were used by non-Nepalese climbers. Only 1 
non-Nepalese enrollee took acetazolamide while trekking up to the base 
camp of Everest. 
Presence of Allergies 
None of the participants reported having any previous allergies at the time 
of enrollment. 
Long term illness 
Three participants responded that they suffered from long term health 
conditions. One non-Nepalese participant had multiple sclerosis. Of the 2 
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Nepalese participants, one suffered from depression and the second from 
alcoholism. 
Breathlessness 
Fifty-one participants responded to this question. 31 (59.6%) responded to 
not having any kind of breathlessness at EBC at baseline, 14 (26.9%) had 
mild whereas 6 (11.5%) reported moderate breathlessness. There was no 
report of severe or incapacitating breathlessness at baseline among 
participants. There was a significant difference between Nepalese and 
non-Nepalese nationality in occurrence of breathlessness (χ2=7.17, P= 
0.028). 
Table 4-2 Distribution of breathlessness by nationality  
Significant difference was observed between the Nepalese and non-Nepalese participants of the study (P= 
0.028). 
 Nepalese Non-Nepalese χ2 P 
Breathlessness 
None 25 6 
7.17 0.028 Mild 12 2 
Moderate 2 4 
4.2. Improvement of cough 
The primary outcome of the study was the variable improvement in 
cough. At follow-up visit, 34 of 40 (85%) participants mentioned that 
their cough had improved. Only 6 (15%) participants reported no change 
in cough status. Among those who reported improvement in cough, 
4(10%) reported little improvement, 7 (17.5%) reported moderate 
improvement, 20 (50%) reported great improvement and 3 (7.5%) 
reported completely resolved cough. Median response was 4 (2.25-4). 
In the placebo group, median response was 4 (greatly improved cough) 
(IQR 3-4), and in treatment group, median response was 4 (greatly 
improved cough) (IQR 1.75-4). 
Among subjects taking treatment (18), 4 (22.2%) reported no 
improvement at all in HAC while the rest had some kind of improvement. 
8 (44.44%) mentioned that their cough improved greatly, and 2 (11.11%) 
out of 18 subjects taking treatment mentioned having completely resolved 
cough. In subjects taking placebo (22), only 2 (9.1%) reported that they 
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had no improvement in cough, the rest reporting improvements of various 
degrees. 12 (54.5%) mentioned great improvement and 1 (4.55%) of 22 
subjects mentioned having completely resolved cough.  Fisher's exact test 
did not show any significant difference between placebo and treatment in 
improving the cough (P= 0.645). 
Analysis of the data by significance of improvement in the treatment and 
placebo arms was carried out. In treatment arm, 8 of 18 (44.4%) did not 
report a significant improvement in cough, whilst a majority (56.4%) 
reporting that their cough improved significantly. In placebo group, 13 of 
22 (59.1%) reported significant improvement in cough, and 40.9% 
reported otherwise. There is no statistically significant difference between 
placebo and treatment groups in terms of significant improvement of 
HAC (P= 0.538). The odds for significant improvement of HAC under 
treatment with combination of fluticasone 250 mcg and salmeterol 50 mcg 
in comparison to placebo is 0.865 with a 95% CI [0.246, 3.050].  
 
 
Figure 4-4 Distribution of improvement of cough by treatment arm 
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Figure 4-5 Distribution of significant improvement of cough at follow up  
Table 4-3 Distribution of improvement in cough by randomization 
 
Randomization 
 
Placebo Treatment 
How Is Your Cough 
Now 
No Improvement 2 (9.1) 4(22.2) 
Fisher's Exact =2.84,  
P = 0.645 
Improved a bit 2(9.1) 2(11.1) 
Improved moderately 5(22.7) 2(11.1) 
Improved greatly 12(54.5) 8(44.4) 
Completely resolved, No cough 1(4.5) 2(11.1) 
 Total 22(100) 18(100) 
 
Table 4-4 Distribution of significant improvement in cough by randomization 
Variable Groups 
Randomization P (Fisher's 
Exact) Placebo Treatment 
Improvement of Cough 
No Significant Improvement of Cough 9 8 
0.538 Significant Improvement of Cough 13 10 
Total 22 18 
  
Effect on nationality on the response to the primary outcome question was 
analyzed across arms. Comparing Nepalese participants versus non-
Nepalese participants, there was no significant difference in the response 
to subjective patient reported improvement in cough at follow up (Z= -
1.84, P= 0.066). 
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Correlation of improvement in cough to other variables 
MLCQ score at follow up 
In placebo arm, we found a significant correlation of improvement of 
cough with the MLCQ score at follow up (Spearman's rho= 0.70, P= 
0.000). Significant correlation was also seen between improvement of 
cough and change in MLCQ score from baseline values (Spearman's rho= 
0.47, P= 0.033). 
In treatment arm also, correlation between improvement of cough and 
MLCQ score at follow up was significant (Spearman's rho= 0.85, P= 
0.000). There was also a significant correlation between improvement of 
cough and change in MLCQ score from baseline values (Spearman's rho= 
0.82, P= 0.000).  
 
Figure 4-6 MLCQ score at follow up to improvement in cough scatterplot 
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Figure 4-7 Change in MLCQ score to improvement in cough scatterplot 
Clinical variables  
Pulse rate, blood pressure, and oxygen saturation at follow up or change in 
their values from baseline did not correlate with improvement in HAC at 
follow up.  
Respiratory function  
Change in FEV1 values from baseline showed a significant positive 
correlation with improvement in cough in the treatment arm (Spearman's 
rho= 0.56, P= 0.015) and a significant negative correlation with 
improvement in cough in the placebo arm (Spearman's rho= -0.50, P= 
0.023).   
PEF values or change in PEF did not correlate with improvement in cough 
at follow up.  
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Figure 4-8 Association between change in FEV1 and improvement in cough 
4.3. Quality of life at baseline 
4.3.1. MLCQ score 
MLCQ was administered to all participants at baseline and response was 
collected from all 52 enrollees except for 1 participant failing to respond 
to questionnaire item number 10. Mean MLCQ score at baseline was 
13.54±3.08. Also at baseline, mean physical domain score for MLCQ was 
4.42±0.99, mean psychological domain score was 4.56±1.247 and mean 
social domain score was 4.58±1.48.  
MLCQ score by nationality of participants 
Mean MLCQ score was 13.55±3.13 for Nepalese participants, whereas for 
non-Nepalese participants mean score was 13.49±3.05. There was no 
difference in quality of life at baseline among Nepalese climbers as 
compared to the non-Nepalese climbers at enrollment (Z= -0.16, P= 
0.876). Similarly, the mean physical domain score for Nepalese 
participants was 4.36±0.98 and for non-Nepalese participants 4.61±1.06; 
there being no statistical difference based on nationality (Z= -0.77, P= 
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0.443). Mean psychological domain score was 4.50±1.31 for Nepalese 
and 4.69±1.08 for non-Nepalese participants; also without a statistical 
difference (Z= -0.66, P= 0.512). Mean social domain scores at baseline 
for Nepalese population was 4.69±1.57. For non-Nepalese participants, 
mean social domain score was 4.19±1.19 which was also not different 
statistically (Z= -1.20, P= 0.231). 
MLCQ scores by gender 
Analyzing the MLCQ scores by gender, we found that in males, the mean 
score was slightly higher (13.55±3.06) than in females (13.41±3.55). 
However, there was no statistical difference between genders (Z= -0.06, 
P= 0.953). Mean physical score in males (4.42±0.98) was very similar to 
that in females (4.43±1.16) with Z-value -0.15 and P 0.884. Mean 
psychological score was also similar between male participants 
(4.54±1.28) and female participants (4.53±1.14) in the study population. 
Test statistics for difference in psychological domain score were Z -0.04 
and P 0.966. Mean social domain score showed a slight difference 
however not statistically (Z= -0.29, P= 0.774). The male gender scored 
higher (4.59±1.50) in an average as compared to female counterparts in 
the study (4.46±1.57). 
MLCQ scores by treatment arm 
MLCQ scores at baseline were also studied to find any differences 
between treatment arm and placebo arm. At baseline, mean MLCQ score 
in the placebo arm was 12.66±3.33 and in the treatment arm was 
14.60±2.41. This difference was significant statistically (Z= -2.10, P= 
0.028). On exploring domain scores, difference was found between the 
arms in physical (Z= -2.38, P= 0.017) domain. Mean physical domain 
score for placebo was 4.12±1.04 and for treatment arm was 4.79±0.81. 
Similarly, mean psychological domain score for placebo arm was 
4.36±1.32, whereas for treatment arm, it was 4.77±1.16. Social domain 
score was 4.19±1.65 for placebo arm and it was 5.04±1.14 for treatment 
arm. Tests failed to show significant statistical difference between placebo 
and treatment arms in psychological (Z= -1.27, P= 0.205) and social 
domains (Z= -1.90, P= 0.058). 
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Figure 4-9 Baseline mean MLCQ score with 95% CI 
There was a significant difference (P= 0.028) between the two arms at baseline. 
Table 4-5 MLCQ score and domain scores at baseline 
 
 Placebo Treatment P Total 
MLCQ Score 12.82±3.29 14.51±2.43 0.028 13.54±3.08 
Physical Domain 4.16±1.03 4.80±0.83 0.017 4.42±0.99 
Psychological Domain 4.4±1.33 4.72±1.16 0.205 4.56±1.25 
Social Domain 4.25±1.65 4.99±1.14 0.058 4.58±1.48 
 
On analyzing the Modified LCQ, the reliability of the 19-item 
questionnaire, calculated in terms of Cronbach’s alpha, was 0.816.  
On analyzing individual questionnaire items, 4 items showed significant 
difference at enrollment between placebo and treatment arms by Mann 
Whitney U test.  
a. Cough interferes with the overall enjoyment of trek (Z= -3.850, P= 
0.000) 
b. During trek, has cough disturbed your sleep?(Z= -2.806, P= 0.005) 
c. During the trek, my cough has made me feel frustrated.(Z= -2.460, P= 
0.014) 
d. During the trek, have you had a lot of energy? (Z= -2.223, P= 0.026) 
Subjects receiving treatment had a higher score, denoting better quality of 
life, than the placebo in these 4 items. There was no difference between 
- 45 - 
 
placebo and treatment groups in other questionnaire items during 
enrollment. 
4.3.2. Physical domain:  
Questionnaire items falling in the physical domain were questions 1, 2, 3, 
4, 10, 11, 12, 14 and 15. These questions assessed the self-reported 
quality of life in terms of physical presence of cough, pain associated, 
sputum production, tiredness attributable, exacerbation by fumes, loss of 
sleep, frequency of coughing bouts, hoarse voice and energy levels in the 
presence of cough. Most subjects came for treatment when median 
subjective cough perception was 3.5. Subjects had chest or stomach pains 
infrequently (median score 7), were not bothered by sputum production 
(median score 5), coughing bouts were present several times during the 
day (median score 3), occasionally suffered from hoarse voice (median 
score 5). Median scores and inter-quartile range for each questionnaire 
item were compared across treatment arms and represented in the table. 
 
 
 
 
Table 4-6 Physical domain questionnaire items at baseline 
Physical Domain 
Placebo Treatment 
N Median IQR N Median IQR 
Have you been troubled by a cough during your trek? 28 3.50 2.00-5.00 24 3.50 2.25-4.00 
During your trek, had chest or stomach pains due to cough? 28 6.00 4.00-7.00 24 7.00 5.00-7.00 
During your trek, have you been tired because of your cough? 28 5.00 3.00-7.00 24 5.00 4.00-7.00 
Have you been bothered by sputum production when you cough? 28 5.00 4.00-6.00 24 5.50 4.00-7.00 
During trek, exposure to smoke or fumes makes me cough 28 4.50 2.00-6.00 23 5.00 5.00-7.00 
During trek, has cough disturbed your sleep? 28 4.00 2.00-5.00 24 6.00 4.00-7.00 
If troubled by cough, how many times/day have had coughing bouts? 28 3.00 1.25-3.00 24 3.00 2.00-4.00 
During trek, have you suffered from hoarse voice from cough? 28 5.00 2.50-6.00 24 5.00 3.00-7.00 
During trek, have you had a lot of energy? 28 4.00 2.00-6.00 24 6.00 4.00-7.00 
4.3.3. Psychological domain: 
Questionnaire items falling in the psychological domain were questions 5, 
6, 7, 13, 16 and 17. These questions assessed the self-reported control, 
embarrassment, anxiety, frustration, worry and concern because of the 
presence of cough. The participants were not embarrassed by the cough 
(median score 5), and generally not concerned that other people thought 
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there was something wrong with them due to cough. Median scores and 
IQR were compared across treatment arms and are represented in the 
table. 
 
Table 4-7 Psychological domain questionnaire items at baseline 
Psychological Domain 
Placebo Treatment 
N Median IQR N Median IQR 
During your trek, have you felt in control of your cough? 28 4.50 2.25-6.00 24 3.50 2.00-5.75 
How often during your trek have you felt embarrassed by coughing? 28 5.00 4.00-7.00 24 5.50 4.00-7.00 
During the trek, my cough has made me feel anxious 28 4.00 2.00-6.00 24 5.00 3.00-6.00 
During trek, my cough has made me feel frustrated 28 3.00 2.00-5.00 24 5.00 4.00-7.00 
During trek, have you worried cough may indicate serious illness 28 5.00 2.50-7.00 24 7.00 3.25-7.00 
Concerned other people think something wrong w/you due to cough? 28 6.00 2.00-7.00 24 5.50 3.00-7.00 
4.3.4. Social domain:  
Questionnaire items in this domain were 8, 9, 18 and 19. Social domain 
assessed the self-reported interference of cough in daily jobs, interference 
in overall enjoyment, interruption in communications and annoyance of 
others as a direct result of cough. Subjects felt that the cough did not 
interfere with the ability to exercise or other tasks (median score 5). 
Median and IQR distribution across treatment arms is represented in the 
table. 
Table 4-8 Social domain questionnaire items at baseline 
Social Domain 
Placebo Treatment 
N Median IQR N Median IQR 
During trek cough interfered w/ability to exercise or other task 28 5.00 4.00-7.00 24 5.00 4.00-7.00 
Cough interferes with overall enjoyment of trek 28 3.00 1.25-4.75 24 5.50 4.00-7.00 
During trek, my cough has interrupted conversation 28 4.00 3.00-6.75 24 4.50 3.25-7.00 
During trek, my cough has annoyed fellow trekkers/tent partner 28 4.00 3.00-7.00 24 5.00 4.00-7.00 
4.4. Quality of life at follow up 
4.4.1. MLCQ score 
At follow up, self-administered MLCQ was analyzed to assess the change 
in the quality of life brought about by the different treatment arms. 
Complete response from 42 participants was available for analysis. The 
items in MLCQ could get a score from 1-7, where 1 is the worst quality of 
life and 7 is the best quality of life possible. At follow-up, Cronbach’s 
alpha for MLCQ was 0.906. 
At follow up, mean MLCQ score was 16.34±3.28, a significant 
improvement (P= 0.000) from the baseline value. In placebo arm, the 
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score was 16.09±3.39 at follow up, also a significant improvement from 
baseline values (P= 0.000). The mean change in MLCQ score from 
baseline value in placebo arm was 3.92 with 95% CI 2.56-5.28. In 
treatment arm, the follow up value of 16.87±3.21 was significantly 
different from baseline value (P= 0.032). The mean change in the 
treatment group was 2.21 with 95% CI 0.36-4.06. There was no statistical 
difference between the treatment arms in the follow up values (P= 0.594) 
as well as between the mean change in MLCQ scores in the respective 
arms (P= 0.166). 
 
 
Figure 4-10 Mean MLCQ score and 95% CI of mean at baseline and follow up 
Table 4-9 MLCQ score and domain scores by randomization at follow up 
 
Placebo Treatment P Total 
MLCQ Score 16.09±3.39 16.87±3.21 0.594 16.34±3.28 
Physical Domain 5.19±.86 5.53±1.13 0.403 5.29±1.02 
Psychological Domain 5.41±1.38 5.66±1.04 0.873 5.45±1.25 
Social Domain 5.41±1.38 5.66±1.04 0.692 5.49±1.47 
 
Table 4-10 MLCQ score and domain scores comparison inside study arms 
 
Placebo Treatment Total 
Baseline Follow Up P Baseline Follow Up P Baseline Follow Up P 
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MLCQ Score 12.82±3.29 16.09±3.39 0.000 14.51±2.43 16.87±3.21 0.032 13.54±3.08 16.34±3.28 0.000 
Physical Domain 4.16±1.03 5.19±.86 0.000 4.80±0.83 5.53±1.13 0.046 4.42±0.99 5.29±1.02 0.000 
Psychological Domain 4.4±1.33 5.41±1.38 0.003 4.72±1.16 5.66±1.04 0.06 4.56±1.25 5.45±1.25 0.000 
Social Domain 4.25±1.65 5.41±1.38 0.000 4.99±1.14 5.66±1.04 0.13 4.58±1.48 5.49±1.47 0.000 
 
4.4.2. Physical domain: 
In placebo arm, mean physical domain score increased significantly to 
5.19±0.86 (P= 0.000) from baseline value. In treatment arm, the follow up 
value of 5.53±1.13 was also significantly different from baseline values 
(P= 0.046). However there was no significant difference between placebo 
and treatment arms at follow up.  
Comparing median scores for individual questionnaire items in the 
physical domain between treatment and placebo arms at baseline and 
follow up, a general trend of increase in scores in seen in most 
questionnaire items. Participants were less troubled by cough at EBC or 
above at follow up in both placebo and treatment arms. Tiredness because 
of cough at baseline in both arms improved to a median score of 6 at 
follow up. Being bothered by sputum production in placebo arm remained 
unchanged but the median score improved in treatment arm. Exposure to 
fumes and smoke causing cough remained unchanged in treatment arm, 
and improved in the placebo arm. Disturbance in sleep attributable to 
cough also improved in both arms and a slight improvement in median 
scores was noted in the frequency of coughing bouts per day. Hoarse 
voice from cough improved to a median score of 7 from a median score of 
5 in both arms.  
Table 4-11 Physical domain summary of statistics at follow up 
Physical Domain 
Placebo Treatment 
N Median IQR N Median IQR 
Have you been troubled by a cough during your trek? 24 5.00 4.00-5.75 18 5.00 3.00-6.25 
During your trek, had chest or stomach pains due to cough? 24 7.00 5.25-7.00 19 6.00 4.00-7.00 
During your trek, have you been tired because of your cough? 23 6.00 5.00-7.00 19 6.00 4.00-7.00 
Have you been bothered by sputum production when you cough? 24 5.00 4.00-5.75 19 6.00 3.00-7.00 
During trek, exposure to smoke or fumes makes me cough 24 5.00 4.00-6.75 18 5.00 4.00-7.00 
During trek, has cough disturbed your sleep? 24 6.00 4.25-7.00 19 7.00 5.00-7.00 
If troubled by cough, how many times/day have had coughing bouts? 24 4.00 3.00-5.00 19 4.00 3.00-6.00 
During trek, have you suffered from hoarse voice from cough? 24 7.00 5.00-7.00 19 7.00 6.00-7.00 
During trek, have you had a lot of energy? 24 6.00 3.25-6.00 19 6.00 4.00-7.00 
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4.4.3. Psychological domain: 
Psychological domain scores improved significantly in placebo group at 
follow up to 5.41±1.38 (P= 0.003). In treatment arm, there was 
improvement in mean scores to 5.66±1.04 but the difference from 
baseline values was not significant (P= 0.058). At follow up, however, 
placebo and treatment arms did not show a statistically significant 
difference (P= 0.873).  
Looking at the individual questionnaire items, there was a trend for 
positive change in median scores at follow up. Feeling of being in control 
of cough improved in both arms at follow up. Embarrassment due to 
cough in both arms at follow up improved to a median score of 7. There 
was overall improvement in feeling of anxiety in placebo arm, and strong 
improvement in frustration levels.  
Table 4-12 Psychological domain summary of statistic at follow up 
Psychological Domain 
Placebo Treatment 
N Median IQR N Median IQR 
During your trek, have you felt in control of your cough? 24 5.00 3.00-6.75 19 5.00 3.00-7.00 
How often during your trek have you felt embarrassed by coughing? 24 7.00 4.00-7.00 19 7.00 4.00-7.00 
During the trek, my cough has made me feel anxious 24 6.50 4.00-7.00 19 5.00 4.00-7.00 
During trek, my cough has made me feel frustrated 24 6.50 4.00-7.00 19 7.00 4.00-7.00 
During trek, have you worried cough may indicate serious illness 24 6.00 4.00-7.00 19 6.00 5.00-7.00 
Concerned other people think something wrong w/you due to cough? 24 6.00 4.00-7.00 19 7.00 5.00-7.00 
4.4.4. Social domain: 
Mean domain scores in social domain showed an increase at follow up 
from the baseline values. In placebo arm, the mean follow up value of 
5.41±1.38 was significantly different from the baseline value (P= 0.000). 
However, in treatment arm, the follow up value of 5.66±1.04 was not 
significantly different from the baseline values (P= 0.127). There was no 
significant difference between the arms in the follow up values for the 
social domain (P= 0.692). 
There was improvement in median score in both arms in the interference 
by cough to exercise. There was improvement in the median score for 
cough interfering in the overall enjoyment of the trek in placebo arm. 
There was big improvement in the median score at follow up in both arms 
in interruption of conversation by cough and annoyance of fellow trekkers 
or tent partners due to cough. 
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Table 4-13 Social domain summary of statistics at follow up 
Social Domain 
Placebo Treatment 
N Median IQR N Median IQR 
During trek cough interfered w/ability to exercise or other task 24 6.00 4.00-7.00 19 6.00 5.00-7.00 
Cough interferes with overall enjoyment of trek 24 6.00 4.00-7.00 19 5.00 4.00-7.00 
During trek, my cough has interrupted conversation 24 5.50 4.00-7.00 19 7.00 3.00-7.00 
During trek, my cough has annoyed fellow trekkers/tent partner 24 6.00 4.00-7.00 19 7.00 6.00-7.00 
4.5. Relation of cough to exercise 
4.5.1. At baseline 
This question was put together with the cough questionnaire, and was a 
self-reported 3 scale question with responses to the question "If you have 
a cough, how often is it related to exercise?" The responses possible were 
'Only brought on by exercise', 'Made worse by exercise', and 'Not related 
to exercise'. 
At baseline, 8 out of 52 (15.4%) respondents answered that their cough 
was brought on by exercise. In contrast, 21 (40.4%) responded that their 
cough was made worse by exercise and 23 (44.2%) responded that 
exercise was not related to cough in any way. In the placebo arm, the 
responses were 2 (7.1%), 9 (32.1%), and 17 (60.7%) respectively. In the 
treatment arm, the responses were 6 (25%), 12 (50%) and 6 (25%) 
respectively. On analyzing the difference between arms with χ2 test, there 
was a significant statistical difference between treatment arms at baseline 
(χ2=7.43, df= 2, P= 0.024). 
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Figure 4-11 Relation of HAC with exercise at baseline 
 
Table 4-14 Relation of cough to exercise at baseline 
 Randomization 
χ2 df P Placebo Treatment 
If you have a cough, how often 
is it related to exercise? 
Only brought on by exercise 2 6 
7.426 2 0.024 Made worse by exercise 9 12 
Not related to exercise 17 6 
4.5.2. At follow up 
At follow up, none of the participants in the treatment arm responded that 
the cough was brought on only by exercise, whereas 3 participants 
(12.5%) responded that exercise was the cause for cough.7 participants in 
placebo (29.2%) and 7 in treatment arm (41.2%) responded that the cough 
was made worse by exercise. 14 (58.3%) in the placebo arm and 10 
(58.8%) in the treatment arm responded at follow up that their cough was 
not related to exercise.  
On χ2 test between placebo and treatment arms, there was no difference 
between the arms at follow up in the distribution of participants regarding 
the relation of cough to exercise. 
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Table 4-15 Distribution of relation of cough to exercise by treatment arm 
 Randomization 
χ2 df P Placebo Treatment 
If you have a cough, how often 
is it related to exercise? 
Only brought on by exercise 3 0 
2.546 2 0.280 Made worse by exercise 7 7 
Not related to exercise 14 10 
 
4.6. Altitude of HAC occurrence 
Most of the participants reported that their cough developed when they 
reached an altitude of 5000-5999 meters. Second most frequent altitude 
where the HAC started was 4000-4999 meters. This proportion was 
similar for Nepalese and non-Nepalese participants of the study.  
Table 4-16 Altitude of HAC occurrence 
Altitude 
Total Placebo Treatment Nepalese Non-Nepalese 
N Percent N Percent N Percent N Percent N Percent 
3000-3999 m 2 3.8 2 7.1     1 2.6 1 7.7 
4000-4999 m 10 19.2 6 21.4 4 16.7 7 17.9 3 23.1 
5000-5999 m 32 61.5 15 53.6 17 70.8 24 61.5 8 61.5 
Above 6000 m 8 15.4 5 17.9 3 12.5 7 17.9 1 7.7 
Total 52 100 28 100 24 100 39 100 13 100 
4.7. Clinical Variables at baseline and follow up 
Pulse rate 
At baseline, average pulse rate for participants with HAC was 
82.37±15.48 per minute. On analyzing by nationality, Nepalese 
participants were found to have lower (81.51±15.50 per minute) pulse rate 
than their non-Nepalese counterparts (84.92±15.77 per minute). This 
difference was not significant between the groups compared (Z= -0.29, P= 
0.775). Female climbers were found to have slightly higher pulse rates 
(85.17±14.26 per minute) than their male counterparts (82.00±15.74 per 
minute), but the difference was not significant (Z= -0.30, P= 0.763). 
Analyzing by treatment arms, baseline pulse rate in treatment arm was 
81.29±16.90 per minute, while in placebo arm, 83.29±14.40 per minute. 
There was no difference on comparison of the two arms (Z= -0.36, P= 
0.693). 
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On follow up, mean pulse rate for the placebo arm was 80.77±9.99 per 
minute, with a mean change of -3.18 per minute (95% CI -9.26, 2.90) 
from its baseline values. This decrease was not significantly different 
though (P= 0.235). In the treatment arm, the pulse rate at follow up was 
87.38±18.12 per minute, a mean change of 5.29 per minute (95% CI -
3.40, 13.99) from the baseline values. The difference with baseline values 
was not significant (P= 0.199). Although the mean change in pulse rate 
between arms was not significantly different (Z= -1.79, P= 0.074), this 
change in treatment arm is in opposite direction to that of placebo arm. 
There was no difference between placebo and treatment arms at follow up 
(P= 0.304). 
Table 4-17 Pulse rate 
 Pulse Rate (per minute) 
Baseline Follow Up Pa Change 
Placebo 83.04±14.61 80.77±9.99 0.235 -3.18±13.71 
Treatment 81.68±17.56 87.38±18.12 0.199 5.29±16.92 
Pb 0.693 0.304 - 0.074 
Total 82.37±15.48 82.65±14.22 0.995 -0.19±14.98 
a: P-value for before after comparison (row) 
b: P-value for between the groups comparison (column) 
 
Oxygen Saturation 
Oxygen saturation measured at baseline was in average 83.06±3.84 
percentage. This was lower in Nepalese participants (82.36±3.89 percent) 
than non-Nepalese participants (85.15±2.88). The difference between the 
groups was significant in this case (Z= -2.16, P= 0.031). Male participants 
seemed to have slightly lower oxygen saturation (82.89±3.88 percent) 
than their female counterparts (84.33±3.50 percent), there being no 
difference between the groups (Z= -1.04, P= 0.300). Analyzing the 
variable at baseline by treatment arm, participants in treatment arm had 
slightly lower (82.58±4.72 percent) saturation than their counterparts in 
the placebo arm (83.46±2.91 percent). However there was no difference 
in oxygen saturation between the treatment and placebo arms (Z= -0.76, 
P= 0.449). 
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Figure 4-12 Distribution of oxygen saturation in Nepalese and non-Nepalese participants at baseline 
At follow up, oxygen saturation showed tendency in both arms to 
increase. With the arms combined, the total increase was significant from 
baseline 83.06±3.84 to follow up value 84.42±4.99 (P= 0.025). On 
analysis of the arms separately, mean increase in placebo arm was from 
1.32 percent (95% CI -0.17, 2.81) to a mean follow up value of 
84.82±4.03 percent. This increase was not significant (P= 0.088). In 
treatment arm, the percentage saturation increased on an average by 1.65 
percent (95% CI -1.32, 4.61) to 83.38±6.56 percent, a change not 
significant (P= 0.169). There was no difference in the mean increase of 
oxygen saturation between the arms (Z= -0.03, P= 0.980). There was no 
difference between placebo arm and treatment arm in the follow up 
oxygen saturation values (P= 0.806). 
 
Table 4-18 Oxygen saturation 
 
SpO2 (%) 
Baseline Follow Up Pa Change 
Placebo 83.63±2.83 84.82±4.03 0.088 1.32±3.36 
Treatment 82.32±4.84 83.38±6.56 0.169 1.65±5.77 
Pb 0.449 0.806 - 0.980 
Total 83.06±3.84 84.42±4.99 0.025 1.37±4.36 
a: P-value for before after comparison (row) 
b: P-value for between the groups comparison (column) 
 
Blood Pressure 
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At baseline, average systolic blood pressure (SBP) was 133.43±14.99 
mmHg. Diastolic blood pressure (DBP) on average was 86.20±12.51 
mmHg. Among the Nepalese participants, SBP was 135.54±15.41 mmHg 
and DBP was87.90±13.31 mmHg. Among non-Nepalese participants, 
SBP was 126.58±11.61 mmHg and DBP was 80.67±7.43 mmHg. This 
comparison by nationality for SBP (Z= -1.87, P= 0.061) and for DBP (Z= 
-1.90, P= 0.058) were statistically not significant although there was 
difference between Nepalese and non-Nepalese participants was seen. In 
the treatment arm, SBP was 137.78±17.13 mmHg and DBP was 
89.04±13.08 mmHg. In the placebo arm, SBP was 129.86±12.16 mmHg 
and DBP was 83.86±11.73 mmHg. Between treatment arms, the 
difference seen in SBP (Z= -1.69, P= 0.091) and DBP (Z= -1.30, P= 
0.192) was not significant.  
Systolic and diastolic blood pressures did not show significant 
fluctuations in both arms between baseline data and follow-up data. SBP 
in the placebo and treatment arms decreased on follow up to 
128.32±16.45 mmHg and 134.13±17.24 mmHg respectively. The mean 
change in SBP in the placebo arm was -2.64 mmHg (95% CI -10.68, 5.40) 
and in treatment arm was -2.94 mmHg (95% CI -11.50, 5.63). There was 
no difference between the arms at follow up (P= 0.227). There was no 
difference in the mean changes between the arms too (P= 0.885). DBP 
showed a marginal increase to 84.27±14.41 mmHg from baseline value in 
the placebo arm. But the mean change was -2.91 mmHg (95% CI -9.59, 
3.77). In the treatment arm, DBP took a dip to 86.19±14.28 mmHg. The 
mean change was -2.06 mmHg (95% CI -8.80, 4.69). There was no 
difference between the DBP values between arms at follow up. The mean 
changes in DBP did not reveal any significant differences between arms. 
Table 4-19 Systolic and Diastolic blood pressure 
 
SBP (mmHg) DBP (mmHg) 
Baseline Follow Up Pa Change Baseline Follow Up Pa Change 
Placebo 129.48±12.23 128.32±16.45 0.279 -2.64±18.14 83.07±11.19 84.27±14.41 0.296 -2.91±15.07 
Treatment 138.68±16.96 134.13±17.24 0.338 -2.94±16.65 89.45±13.23 86.19±14.28 0.678 -2.06±13.12 
Pb 0.091 0.227 - 0.885 0.192 0.721 - 0.784 
Total 133.43±14.99 130.62±16.07 0.181 -2.95±16.92 86.20±12.51 84.71±13.90 0.251 -2.35±13.94 
a: P-value for before after comparison (row) 
b: P-value for between the groups comparison (column) 
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Peak expiratory flow 
Measurement at baseline revealed an average PEF of 8.79±2.77 
liters/second among all participants. Nepalese participants sported an 
average PEF of 8.24±2.65 liters/second. Average for non-Nepalese 
participants was 10.19±2.71 liters/second. There was a significant 
statistical difference in PEF by nationality in the study population (Z= -
2.08, P= 0.037). PEF measurement by gender yielded no statistical 
difference between male and female participants. Average PEF for males 
in the study was 8.71±2.73 liters/second, whereas for females was 
8.92±3.34 liters/second, with the Z-value being -0.14 and P-value 0.886. 
Average PEF value for placebo arm was higher (9.29±2.85 liters/second) 
than average PEF in the treatment arm (8.11±2.60 liters/second). 
However, there was no statistical difference between the treatment arms at 
baseline (Z= -1.55, P= 0.121). 
 
Figure 4-13 PEF distribution at baseline among Nepalese and non-Nepalese participants at baseline 
PEF in placebo arm was 10.10±3.35 at follow up, significantly different 
from baseline values (P= 0.021). The mean difference in PEF from 
baseline values was 0.58 liters/second (95% CI -0.44, 1.61). In the 
treatment arm, PEF was 9.16±2.68 at follow up, which was not 
significantly different to baseline values. The mean difference in 
treatment arm was 0.70 liters/second with 95% CI -0.48, 1.87. The mean 
differences between the arms did not show any significant differences (Z= 
-0.49, P= 0.625). 
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Table 4-20 Peak expiratory flow 
 
PEF (liters per second) 
Baseline Follow Up Pa Change 
Placebo 9.29±2.85 10.10±3.35 0.021 0.59±2.32 
Treatment 7.89±2.57 9.16±2.68 0.117 0.70±2.29 
Pb 0.121 0.076 - 0.625 
Total 8.79±2.77 9.54±2.99 0.006 0.53±2.19 
a: P-value for before after comparison (row) 
b: P-value for between the groups comparison (column) 
 
Forced expiratory volume in first second (FEV1) 
Mean FEV1 at baseline in the study population was 3.62±1.01 liters. 
Mean among Nepalese participants was 3.61±0.98 liters and among non-
Nepalese participants 3.65±1.15 liters. There was no significant statistical 
difference in FEV1 on comparing by nationality (Z= -0.20, P= 0.846). 
Comparing by gender, male participants had a higher average FEV1 
(3.70±0.95 liters) than female climbers (3.03±1.35 liters). This was 
statistically different (Z= -2.09, P= 0.037).  
 
Figure 4-14 FEV1 distribution by gender at baseline 
Similarly, analyzing at baseline by treatment arms, mean FEV1 was 
3.85±1.08 liters in placebo and 3.36±0.88 liters in salmeterol/fluticasone 
treatment arm. There was no significant statistical difference between the 
treatment arms (Z= -1.56, P= 0.119) at baseline in this regard too.   
Standard and predicted values for Nepalese population are not available. 
FEV1 and PEF at enrollment are lower than predicted values for a 35 
years 170 cm Caucasian male (predicted FEV1 3.96 liters, P= 0.02; 
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predicted PEF 9.57 liters/second, P= 0.046) [74, 75]. Using predicted 
values for Indian population for same age group [76], FEV1 is 
significantly higher (P= 0.033, predicted FEV1 = 3.31 liters). 
On analyzing FEV1 values, the data showed an improvement over time in 
both treatment and placebo arms in this study. On analyzing total values 
at baseline and follow up, there was a significant change over time (P= 
0.049). In placebo arm, there was a mean increase in FEV1 by 0.12 liters 
(95% CI -0.26, 0.49). Mean increase in the treatment arm was 0.39 liters 
(95% CI -0.04, 0.75). There was no difference between placebo and 
treatment arms in the increase in FEV1 from baseline (Z= -0.87, P= 
0.383).  
Table 4-21 FEV1 
 
FEV1 (liters) 
Baseline Follow Up Pa Change 
Placebo 3.85±1.08 3.95±1.04 0.369 0.11±0.85 
Treatment 3.35±.87 3.88±.98 0.059 0.36±0.77 
Pb 0.119 0.633 - 0.383 
Total 3.62±1.01 3.85±1.00 0.049 0.23±0.79 
a: P-value for before after comparison (row) 
b: P-value for between the groups comparison (column) 
4.8. Symptom checklist at baseline 
The 14-symptom checklist was analyzed to see the presence of 
accompanying symptoms in HAC. The symptoms assessed were related to 
severity of cough, gastro-esophageal reflux and postnasal drip syndrome. 
4.8.1. Symptoms of cough severity 
Retching or vomiting while coughing 
Retching or vomiting while coughing was also complained by participants 
in the study. A total of 23 (44.23%) participants at baseline complained of 
this symptom. Among these, 13 were in placebo arm and 10 in the 
treatment arm. In total, 12 (23.08%) participants reported moderate to 
severe symptoms of retching or vomiting. There was no difference at 
baseline in symptom severity of retching or vomiting while coughing 
between treatment arms (Z= -0.971, P= 0.331). 
Chest tightness or wheezing on coughing 
Chest tightness or wheezing on coughing was reported in 32 (61.54%) 
participants at baseline. 75% (21 of 28) participants in the placebo arm 
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complained of tightness in chest or wheezing in comparison to the 
treatment arm where only 45.83% (11 of 24) participants reported the 
same symptom. The difference between the treatment and placebo arms 
was significant for the symptom of chest tightness or wheezing on 
coughing (Z= -2.016, P= 0.044). 21 participants in total complained of 
moderate to severe symptom, 14 of these in placebo arm and 7 in 
treatment arm. 
Cough while eating  
Cough while eating was reported by 24 (46.15%) participants at baseline. 
In placebo arm, 57.14% (16 of 28) of participants reported cough while 
eating and 8 (28.57%) of these reported of moderate to severe symptom. 
In treatment arm, 33.33% (8 of 24) of participants reported any form of 
cough while eating and 3 (12.5%) of these has moderate to severe 
symptoms at baseline. Statistically, there was no difference between the 
two arms at baseline (Z= -1.60, P= 0.110). 
Cough with certain foods 
Symptom of cough with certain foods was present in 23 (44.23%) 
participants at baseline. In placebo arm, 57.14% (16 of 28) participants 
reported any form of symptom and 3 (10.71%) of these reported of 
moderate to severe symptom. In treatment arm, 29.17% (7 of 24) of 
participants reported cough with certain foods and 3 (12.5%) of these 
complained moderate to severe symptoms at baseline. There was no 
statistical difference between the two arms of study at baseline (Z= -1.35, 
P= 0.177). 
Cough when getting out of bed in morning 
73.08% (38 of 52) of the participants at baseline complained of the 
symptom of cough when getting out of bed in morning. Of these, 20 of 52 
(38.46%) at baseline suffered from moderate to severe problem with 
cough while getting out of bed in morning, 13 were from placebo and 7 
from the treatment arm. 71.43% (20 of 28) participants of the placebo arm 
and 75% (18 of 24) participants of the treatment arm reported of cough 
while getting out of bed. There was no difference between the study arms 
in regards to this symptom at baseline (Z= -0.59, P= 0.555). 
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Cough brought on by speaking or singing 
Cough brought on by speaking or singing was reported in any severity by 
38 (73.08%) of 52 participants at baseline, 26 of these (50%) suffered 
from moderate to severe symptom of coughing while speaking or singing. 
In placebo arm, 21 of 28 (75%) participants reported any kind of cough 
brought on by speaking or singing and 13 (46.43%) reported moderate to 
severe symptom. In treatment arm, 17 of 24 (70.83%) participants 
reported this symptom and 13 (54.17%) of these participants complained 
of moderate to severe symptom. There was no difference between the 
study arms (Z= -0.37, P= 0.708) at baseline in terms of symptom severity 
for cough brought on by speaking or singing. 
Coughing more while awake than while asleep 
41 of the 52 (78.85%) participants at baseline complained of coughing 
more while awake than while asleep, 32 of these had moderate to severe 
symptom. In placebo arm, 23 of 28 (82.14%) participants reported 
symptoms and 19 complained of moderate to severe symptom of 
coughing more while awake. In treatment arm, 19 of 24 (79.17%) 
reported this symptom, while 13 among those reported moderate to severe 
symptoms. There was no difference between the treatment arms at 
baseline regarding this symptom (Z= -1.14, P= 0.254). 
4.8.2. Symptoms of gastro-esophageal reflux and postnasal drip 
Hoarseness 
Some kind of hoarseness was reported by 33 of 52 (63.5%) study 
participants. In the placebo arm, 17 of 28 (60.71%) complained of 
hoarseness at baseline. 16 of 24 (66.67%) participants in treatment arm 
complained of some form of hoarseness at baseline. 15 (28.85%) 
participants in total complained of moderate-severe hoarseness along with 
HAC. The distribution of symptom severity by treatment arms is 
presented in table 4-8. On comparing between treatment and placebo arm, 
there was no significant statistical difference at baseline among treatment 
arms in symptom severity for hoarseness (Z= -0.07, P= 0.947). 
Clearing of throat  
Clearing of throat of any severity was complained by39 (75%), of total 
baseline population, 18 (34.62%) participants reported moderate to severe 
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symptom. In placebo arm, 82.14% (23 of 28) of the participants reported 
symptom of clearing their throat, 10 of these with moderate to severe 
symptom. In treatment arm, 66.67% (16 of 24) of participants reported the 
symptom with 8 participants having a significant problem (moderate to 
severe).  At baseline, comparison between treatment and placebo arm did 
not reveal significant statistical differences (Z= -0.47, P= 0.640) 
Postnasal drip 
Participants complained of some kind of postnasal drip in 26 of 52 (50%) 
at baseline. Among participants in placebo arm and treatment arm the 
percentage was 50% for both. In total, 18 (34.62%) participants reported 
of moderate to severe post nasal drip with HAC at baseline. There was no 
difference between treatment arms at baseline in terms of symptom 
severity for postnasal drip (Z= -0.54, P= 0.587). 
Cough on lying down or bending over 
Cough on lying down or bending over was reported in some form by 
39(75%) participants. In placebo arm, 22 of 28 (78.57%) complained of 
some form of cough on lying down or bending. 17 of 24 (70.83%) in 
treatment arm reported of this symptom in some form. Participants 
complaining of moderate to severe symptom were 13 of 52 (25%) at 
baseline, 10 of these were from placebo arm. There was no difference in 
symptom severity at baseline between the two treatment arms (Z= -1.904, 
P= 0.057). 
Heartburn, stomach acid or indigestion 
18 of 52 (34.62%) participants at baseline complained of heartburn, 
indigestion or stomach acid. In placebo arm, 10 participants of 28 
(35.71%) reported this symptom and in treatment arm 8 of 24 (33.33%) 
complained. There was no difference between the two arms on 
comparison (Z= -0.054, P= 0.957). Among the 18 participants with 
symptom, 12 (66.67%) complained of moderate to severe symptom of 
heartburn, indigestion or stomach acid and 8 participants reported severe 
symptoms.  
Tickle or lump in throat 
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Tickle or lump in throat of any severity was present in 34 (65.38%) 
participants at baseline, with moderate to severe symptoms in 16 
(30.77%) participants. In placebo arm, 67.86% (19 of 28) participants 
reported some sort of tickle or lump in throat and 10 among them reported 
moderate to severe symptom. In treatment arm, 62.5% (15 of 24) 
participants reported some sort of tickle or lump in throat and 6 of them 
reported moderate to severe symptom. There was no statistical difference 
between the two arms at baseline (Z= -1.163, P= 0.245). 
Strange taste in mouth 
Strange taste in mouth was complained by 15.38% (8) participants at 
baseline, 5 from placebo arm and 3 from treatment arm. 5 among these 8 
in total had moderate to severe symptoms. There was no difference 
between placebo and treatment arms (Z= -0.53, P= 0.599). 
 
Table 4-22 Symptom severity distribution at baseline by randomization 
Symptoms Randomization 
Arm 
Symptom Severity 
No 
Problem 
Little 
Problem 
Mild 
Problem 
Moderate 
Problem 
Big 
Problem 
Severe 
Problem 
Hoarseness Placebo 11 6 3 3 2 3 
Treatment 8 8 1 4 3 0 
Clearing your throat Placebo 5 9 4 5 3 2 
Treatment 8 3 5 4 3 1 
Postnasal Drip Placebo 14 0 2 7 2 3 
Treatment 12 1 5 3 1 2 
Retching or vomiting while 
coughing 
Placebo 15 2 3 1 4 3 
Treatment 14 4 2 4 0 0 
Cough on lying down or bending 
over 
Placebo 6 4 8 4 1 5 
Treatment 7 7 7 3 0 0 
Chest tightness or wheeze when 
coughing 
Placebo 7 1 6 6 6 2 
Treatment 13 3 1 3 2 2 
Heartburn, stomach acid or 
indigestion 
Placebo 18 1 2 1 3 3 
Treatment 16 2 1 0 0 5 
Tickle or lump in throat Placebo 9 1 8 3 2 5 
Treatment 9 5 4 2 3 1 
Cough with eating Placebo 12 3 5 6 2 0 
Treatment 16 0 5 2 1 0 
Cough with certain foods Placebo 12 9 4 2 1 0 
Treatment 17 1 3 1 0 2 
Cough when you get out of bed in 
morning 
Placebo 8 4 3 4 4 5 
Treatment 6 1 10 4 2 1 
Cough brought on by speaking or 
singing 
Placebo 7 3 5 4 4 5 
Treatment 7 1 3 8 4 1 
Coughing more when awake than 
asleep 
Placebo 5 2 1 3 11 5 
Treatment 5 1 5 3 8 2 
Strange taste in your mouth Placebo 23 1 1 1 1 1 
Treatment 21 1 0 1 0 1 
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Table 4-23 Baseline differences in symptom severity between randomization arms 
  Placebo Treatment Z 
Asymp. Sig. 
(2-tailed) Median IQR Median IQR 
Hoarseness 1 3 1 3 -0.07 0.947 
Clearing your throat 1.5 2 2 3 -0.47 0.640 
Postnasal Drip 1 3 0.5 2.75 -0.54 0.587 
Retching or vomiting while coughing 0 3.75 0 1.75 -0.97 0.331 
Cough on lying down or bending over 2 2 1 2 -1.90 0.057 
Chest tightness or wheeze when coughing 2.5 3.75 0 3 -2.02 0.044 
Heartburn, stomach acid or indigestion 0 2.75 0 1.75 -0.05 0.957 
Tickle or lump in throat 2 3.75 1 2.75 -1.16 0.245 
Cough with eating 1 3 0 2 -1.60 0.110 
Cough with certain foods 1 1.75 0 1.75 -1.35 0.177 
Cough when you get out of bed in morning 2 4 2 2.75 -0.59 0.555 
Cough brought on by speaking or singing 2 3.75 3 3 -0.37 0.708 
Coughing more when awake than asleep 4 3 3 2.75 -1.14 0.254 
Strange taste in your mouth 0 0 0 0 -0.53 0.599 
4.8.3. Comparison of the symptoms by nationality of the enrollees 
To see whether at baseline, being a Nepalese (N=39) or a non-Nepalese 
(N=13) would make a difference in the reporting of symptom severity, we 
described the symptom severity frequency and compared the two groups 
of nationality by non-parametric tests. At baseline, between the two 
groups, there was difference only in 1 symptom severity in reporting. The 
symptom cough when you get out of bed in the morning was significantly 
difference between Nepalese and non-Nepalese participant groups (Z= -
2.08, P= 0.037). 
  
Table 4-24 Symptom severity at baseline by nationality of participants 
Symptoms Nationality Symptom Severity 
No 
Problem 
Little 
Problem 
Mild 
Problem 
Moderate 
Problem 
Big 
Problem 
Severe 
Problem 
Hoarseness Nepalese 14 9 4 5 4 3 
Non-Nepalese 5 5 0 2 1 0 
Clearing your throat Nepalese 12 7 5 7 5 3 
Non-Nepalese 1 5 4 2 1 0 
Postnasal Drip Nepalese 21 1 7 4 3 3 
Non-Nepalese 5 0 0 6 0 2 
Retching or vomiting 
while coughing 
Nepalese 23 5 4 3 2 2 
Non-Nepalese 6 1 1 2 2 1 
Cough on lying down or 
bending over 
Nepalese 7 8 15 6 0 3 
Non-Nepalese 6 3 0 1 1 2 
Chest tightness or wheeze 
when coughing 
Nepalese 14 2 6 8 5 4 
Non-Nepalese 6 2 1 1 3 0 
Heartburn, stomach acid 
or indigestion 
Nepalese 25 2 2 1 1 8 
Non-Nepalese 9 1 1 0 2 0 
Tickle or lump in throat Nepalese 16 4 8 4 3 4 
Non-Nepalese 2 2 4 1 2 2 
Cough with eating Nepalese 22 3 6 5 3 0 
Non-Nepalese 6 0 4 3 0 0 
Cough with certain foods Nepalese 19 9 5 3 1 2 
Non-Nepalese 10 1 2 0 0 0 
Cough when you get out Nepalese 13 3 10 7 4 2 
- 64 - 
 
of bed in morning Non-Nepalese 1 2 3 1 2 4 
Cough brought on by 
speaking or singing 
Nepalese 12 4 4 9 6 4 
Non-Nepalese 2 0 4 3 2 2 
Coughing more when 
awake than asleep 
Nepalese 8 1 4 4 16 6 
Non-Nepalese 2 2 2 2 3 1 
Strange taste in your 
mouth 
Nepalese 32 2 0 2 1 2 
Non-Nepalese 12 0 1 0 0 0 
 
Table 4-25 Baseline differences in symptom severity by nationality of participants 
  Z Asymp. Sig. 
(2-tailed) 
Hoarseness -0.72 0.469 
Clearing your throat -0.10 0.923 
Postnasal Drip -1.36 0.173 
Retching or vomiting while coughing -1.12 0.263 
Cough on lying down or bending over -1.21 0.228 
Chest tightness or wheeze when coughing -0.85 0.393 
Heartburn, stomach acid or indigestion -0.65 0.516 
Tickle or lump in throat -1.43 0.154 
Cough with eating -0.58 0.563 
Cough with certain foods -1.73 0.084 
Cough when you get out of bed in morning -2.08 0.037 
Cough brought on by speaking or singing -0.91 0.365 
Coughing more when awake than asleep -1.06 0.291 
Strange taste in your mouth -0.93 0.355 
 
4.9. Symptom checklist at follow up 
On analysis of the symptom checklist during follow up, severity of 
symptoms at follow up were reported and compared between treatment 
and placebo arms. In addition, change in symptom severity was examined 
and compared between study arms. Possible association of change in 
symptom severity with improvement in cough status was examined by 
Spearman rank correlation in each treatment arm. Association of change 
in symptom severity score to cough-related quality of life was examined 
also with Spearman rank correlation coefficient between change in 
MLCQ score and change in cough related symptom severity.  
At follow up, almost all of the symptoms showed a marked reduction in 
symptom severity, this reduction in agreement with the improvement in 
cough and a positive mean change in MLCQ score. The symptom severity 
reduction was marked in both arms of the study. 
4.9.1. Symptoms of cough severity 
Retching or vomiting while coughing 
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At follow up, 72.09% (31of 43) of participants did not retch or vomit 
while coughing, while at baseline, compared to 55.77% at baseline (29 of 
52). In placebo arm at follow up, 29.17% (7 of 24) of the participants 
complained of this symptom and 2 had moderate to severe symptom for 
retching or vomiting with cough. In treatment arm, 26.32% (5 of 19) 
participants complained of this symptom and 2 had moderate to severe 
symptom. There was no statistical difference between the randomization 
arms at follow up regarding this symptom (Z= -0.16, P= 0.877). 
Chest tightness or wheeze when coughing 
At follow up, 67.44% (29 of 43) of participants responded that they did 
not have any tightness or wheezing in chest while coughing, compared to 
38.46% (20 of 52) participants at baseline. In placebo arm, 7 (29.17%) of 
24 participants at follow up complained of tightness in chest or wheezing 
while coughing, 2 of these had moderate-severe symptoms. In treatment 
arm, 7 (36.84%) of 19 participants still had tightness in chest or wheezing 
while coughing and 4 had moderate to severe symptom. Statistically, there 
was no difference between the randomization arms at follow up (Z= -0.74, 
P= 0.462). 
Cough while eating 
At follow up, 76.74% (33 of 43) participants did not cough while eating 
compared to 53.85% (28 of 52) participants at baseline. In the placebo 
arm, 20.83% (5 of 24) participants at follow up reported coughing while 
eating, none of these reported moderate to severe symptom. In the 
treatment arm, 26.3% (5 of 19) participants reported cough while eating, 1 
of these reported moderate to severe cough. Statistically, there was no 
difference between the placebo and treatment arm (Z= -0.53, P= 0.596). 
Cough with certain foods 
At follow up, percentage of participants without any symptom of 
coughing with certain foods was 73.81% (31 of 42) compared to the 
baseline 55.77% (29 of 52) participants. In the placebo arm, 26.09% (6 of 
23) participants at follow up reported coughing with certain foods, 3 of 
these reported moderate to severe symptom. In the treatment arm, 26.32% 
(5 of 19) participants reported cough with certain foods, and 1 of these 
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reported moderate to severe cough. Statistically, there was no difference 
at follow up between the placebo and treatment arm (Z= -0.12, P= 0.909). 
Cough when getting out of bed in morning 
At follow up, 62.79% (27 of 43) percentage of participants reported the 
symptom of cough while getting out of the bed in the morning, a decrease 
from the baseline  increase from the baseline 73.08% (38of 52). Of these 
who reported the symptom, 11 suffered from moderate to severe 
symptom. In placebo arm, out of 24 participants in the arm, 15 (62.5%) 
complained of cough when getting out of bed in the morning and 5 
(20.83%) of them reported moderate to severe symptom. In treatment 
arm, out of 19 participants in the arm, 12 (63.16%) reported the symptom 
and 6 complained of moderate to severe symptoms. There was no 
significant statistical difference between placebo and treatment arms at 
follow up regarding this symptom (Z= -0.81, P= 0.417). 
Cough brought on by speaking or singing 
At follow up, 65.12%% (28 of 43) of participants reported the symptom 
of coughing brought on by speaking or singing as compared to the 
baseline percentage of 73.08%% (38 of 52). Of these reporting symptom 
at follow up, 9 suffered from moderate to severe symptoms. In placebo 
arm, out of 24 participants in the arm, 16 (66.67%) complained of cough 
while speaking or singing and 4 of them reported moderate to severe 
symptom. In treatment arm, out of 19 participants in the arm, 12 (63.16%) 
reported the symptom and 5 complained of moderate to severe symptoms. 
There was no significant statistical difference between the placebo and 
treatment arms at follow up regarding cough brought on by speaking or 
singing (Z= -0.39, P= 0.694). 
Coughing more when awake than while asleep 
At follow up, 73.81% (31 of 42) of participants reported the symptom of 
coughing more when awake than while asleep as compared to the baseline 
percentage of 80.77% (42 of 52). Of those reporting symptoms at follow 
up, 20 suffered from moderate to severe symptom. In placebo arm, out of 
24 participants in the arm, 18 (75%) complained of the symptom and 8 of 
them reported moderate to severe symptom. In treatment arm, out of 18 
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participants in the arm, 13 (72.22%) reported the symptom and of these 12 
complained of moderate to severe symptoms. There was no difference 
between the randomization arms at follow up on comparing the symptoms 
statistically (Z= -1.45, P= 0.147). 
4.9.2. Symptoms of cough related to gastro-esophageal reflux and postnasal drip 
Hoarseness 
At follow up, 67.44% (29 of 43) of the participants reported that they did 
not suffer from any symptom of hoarseness, a big increase from baseline 
36.54% (19 of 52). Of the 14 at follow up who reported hoarseness, 7 
suffered from moderate to severe symptoms. At follow up, in the placebo 
arm, there were 29.17% (7 of 24) of participants with hoarseness, 4 of 
these had moderate to severe problem with the symptom. In treatment 
arm, at follow up, 36.84% (7of 19) of the participants had hoarseness, of 
these, 3 had moderate to severe problem with the symptom. No significant 
statistical difference was observed at follow up on comparing the 
treatment arms (Z= -0.47, P= 0.638). 
Clearing of throat 
At follow up, of the 43 participants followed up, 48.84% (21) reported 
that they suffered the symptom of clearing throat and 10 of these still had 
moderate to severe symptoms. This was a big decrease from the baseline 
value of 75% participants who suffered from clearing the throat. At follow 
up, in the placebo arm (N=24), there were 11 (45.83%) participants with 
the symptom of throat clearance, 4 of these had moderate to severe 
symptom severity. In treatment arm, at follow up (N=19), 10 (52.63%) 
participants had the symptom and of these, 6 had moderate to severe 
symptom severity. No significant statistical difference was observed 
between randomization arms at follow up regarding the symptom clearing 
your throat (Z= -0.91, P= 0.363). 
Postnasal drip 
At baseline, 50% of the participants suffered from some form of postnasal 
drip, and at follow up, only 27.91% (12 of 43), and 4 of these 12 suffered 
from moderate to severe symptom. At follow up, in the placebo arm 
(N=24), there were 6 (25%) participants with the post nasal drip, 2 of 
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these had moderate to severe symptom severity. In treatment arm, at 
follow up (N=19), 6 (31.58%) participants suffered from postnasal drip 
and of these, 2 had moderate to severe problem with the symptom. There 
was no statistical difference between placebo and treatment arms at follow 
up regarding postnasal drip (Z= -0.62, P= 0.535). 
Cough on lying down or bending over 
48.84% (21 of 43) of participants at follow up suffered the symptom 
coughing on lying down or bending over, compared to 75% of the 
participants at baseline (39 of 52) at baseline. In placebo arm, out of 24 
participants in the arm at follow up, 15 (62.5%) complained of coughing 
on lying down or bending over and 5 of them reported moderate to severe 
symptom. In treatment arm, out of 19 participants in the arm, 6 (31.58%) 
reported the symptom and 3 complained of moderate to severe symptoms. 
No significant difference was observed in statistical comparison of the 
randomization arms at follow up (Z= -1.63, P= 0.104). 
Heartburn, stomach acid or indigestion 
At follow up, among 42 responses, 30 (71.43%) responses were 0 (no 
problem) in the symptom heartburn, stomach acid or indigestion. Among 
the rest, 5 participants suffered from moderate to severe symptoms even at 
follow up. To compare, at baseline, 34 (65.38%) participants did not think 
that the symptom caused any problems. New treatment of acid 
suppression was not started during the study period. In placebo arm 
(N=23), 8 (34.78%) complained of this symptom, and 4 had moderate to 
severe heartburn, stomach acid or indigestion. In treatment arm (N=19), 4 
(21.05%) complained of heartburn, stomach acid or indigestion and 
1participant suffered from moderate to severe symptoms. At follow up, 
statistical comparison between placebo and treatment arms did not lead to 
any significant difference between the arms (Z= -1.14, P= 0.253). 
Tickle or lump in throat 
At follow up, tickle or lump in throat did not cause any problems in 
72.09% (31 of 43) participants at follow up, compared to 18 of 52 
(34.62%) at baseline. In placebo arm at follow up (N=24), 8 (33.33%) 
participants complained of tickle and lump on throat and 2 of these had 
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moderate to severe symptoms. Similarly, in the treatment arm (N=19), 4 
(21.05%) participants reported the symptom, 3 reported that the symptom 
severity was moderate to severe. Statistically there was no significant 
difference between placebo and treatment arms at follow up in the 
symptom severity of tickle or lump in the throat (Z= -0.64, P= 0.525) 
Strange taste in mouth 
36 of 43 (83.72%) participants at follow up did not report any strange 
taste in mouth, compared to 44 of 52 (84.61%) at baseline. In placebo 
arm, out of 24 participants in the arm, 2 (8.33%) complained of strange 
taste in mouth and none of them reported moderate to severe symptom. In 
treatment arm, out of 19 participants in the arm, 5 (26.32%) reported the 
symptom and 2 complained of moderate to severe symptoms. Statistically, 
no significant difference was observed at follow up between placebo and 
treatment arms in the symptom strange test in mouth (Z= -1.68, P= 
0.094). 
 
Table 4-26Symptom severity in randomization arms at follow up 
  No 
Problem 
Little 
Problem 
Mild 
Problem 
Moderate 
Problem 
Big 
Problem 
Severe 
Problem 
Hoarseness Placebo 17 2 1 3 1 0 
Treatment 12 3 1 1 2 0 
Clearing your throat Placebo 13 5 2 2 2 0 
Treatment 9 2 2 2 3 1 
Postnasal Drip Placebo 18 2 2 2 0 0 
Treatment 13 0 4 1 1 0 
Retching or vomiting while 
coughing 
Placebo 17 2 3 1 0 1 
Treatment 14 1 2 2 0 0 
Cough on lying down or 
bending over 
Placebo 9 4 6 4 0 1 
Treatment 13 1 2 2 1 0 
Chest tightness or wheeze 
when coughing 
Placebo 17 3 2 1 0 1 
Treatment 12 1 2 3 1 0 
Heartburn, stomach acid or 
indigestion 
Placebo 15 2 2 2 2 0 
Treatment 15 2 1 1 0 0 
Tickle or lump in throat Placebo 16 6 0 1 1 0 
Treatment 15 1 0 2 1 0 
Cough with eating Placebo 19 3 2 0 0 0 
Treatment 14 2 2 1 0 0 
Cough with certain foods Placebo 17 2 1 2 0 1 
Treatment 14 2 2 1 0 0 
Cough when you get out of 
bed in morning 
Placebo 9 6 4 4 1 0 
Treatment 7 1 5 4 1 1 
Cough brought on by 
speaking or singing 
Placebo 8 5 7 1 3 0 
Treatment 7 2 5 1 3 1 
Coughing more when 
awake than asleep 
Placebo 6 4 6 4 2 2 
Treatment 5 0 1 4 6 2 
Strange taste in your mouth Placebo 22 2 0 0 0 0 
Treatment 14 2 1 0 1 1 
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Table 4-27 Differences in symptom severity at follow up between treatment and placebo arms 
  Z Asymp. Sig. 
(2-tailed) 
Hoarseness -0.47 0.638 
Clearing your throat -0.91 0.363 
Postnasal Drip -0.62 0.535 
Retching or vomiting while coughing -0.16 0.877 
Cough on lying down or bending over -1.63 0.104 
Chest tightness or wheeze when coughing -0.74 0.462 
Heartburn, stomach acid or indigestion -1.14 0.253 
Tickle or lump in throat -0.64 0.525 
Cough with eating -0.53 0.596 
Cough with certain foods -0.12 0.909 
Cough when you get out of bed in morning -0.81 0.417 
Cough brought on by speaking or singing -0.39 0.694 
Coughing more when awake than asleep -1.45 0.147 
Strange taste in your mouth -1.68 0.094 
 
4.9.3. Change in symptom severity at follow up 
Analysis of how the symptom severity changed over time, between 
baseline and follow up values, in treatment and placebo arms was 
explored. Since symptom severity was in a 0-5 response scale, differences 
in median values were taken to represent the change in symptom severity 
brought about by treatment regimen.  
In the placebo arm, there was no positive change in median scores, 9 of 
the 14 symptoms showed a negative change in median score from 
baseline values, reflecting an improvement in the severity of the 
symptoms. 5 symptoms at follow up showed no change from baseline 
values.  
In the treatment arm, only 3 symptoms showed a negative change in the 
median values of symptom severity at follow up. Most of the symptoms 
did not show a median change from baseline values. The summary of the 
changes is shown in the table 4-27.  
Table 4-28 Difference between placebo and treatment arms in the change of symptom severity from baseline 
  Z Asymp. Sig. (2-tailed) 
Hoarseness -0.84 0.400 
Clearing your throat -1.24 0.216 
Postnasal Drip -0.96 0.339 
Retching or vomiting while coughing -0.90 0.371 
Cough on lying down or bending over -0.76 0.445 
Chest tightness or wheeze when coughing -2.09 0.037 
Heartburn, stomach acid or indigestion -0.35 0.729 
Tickle or lump in throat -1.42 0.156 
Cough with eating -1.96 0.050 
Cough with certain foods -0.73 0.465 
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Cough when you get out of bed in morning -1.84 0.066 
Cough brought on by speaking or singing -1.08 0.278 
Coughing more when awake than asleep -1.58 0.115 
Strange taste in your mouth -2.44 0.015 
 
On comparing the two randomization arms, a significant difference was 
seen in between the placebo and treatment arms in the change of symptom 
severity in 3 symptoms.  
The change in symptom severity of chest tightness or wheezing while 
coughing was significantly different between the placebo and treatment 
arms (Z= -2.09, P= 0.037).  The median change in this symptom from 
baseline was -2.00 with an IQR of 3 in the placebo arm, while in the 
treatment arm; the median change in symptom severity was 0.00 with an 
IQR of 2. 
The change in symptom severity of cough with eating was significantly 
different between placebo and treatment arms (Z= -1.96, P= 0.050). The 
median change in the symptom severity for the placebo arm was -1.00 
with an IQR 2, while in the treatment arm; the change was 0.00 with an 
IQR of 1.  
The other symptom for which the change in severity was significantly 
different between placebo and treatment arms was strange taste in mouth 
(Z= -2.44, P= 0.015). Both in the placebo and treatment arms, the median 
change in symptom severity for strange taste in mouth was 0.00 with an 
IQR 0.25. 
4.9.4. Correlation of change in symptom severity to improvement in cough 
In placebo arm of the study, the symptoms explored did not show any 
correlation between symptom severity and level of improvement in cough 
apart from cough while speaking or singing (Spearman's rho= -0.51, P= 
0.015). In the treatment arm, correlation coefficients were statistically 
significant. All the significant coefficients were negative, implying that an 
increase in the level of improvement was reflected by a decrease in the 
symptom severity. Hoarseness, cough on lying down or bending over, 
chest tightness or wheezing when coughing, heartburn, stomach acid or 
indigestion, tickle or lump in throat, cough when getting out of bed in 
morning, and coughing more when awake than asleep were associated 
with improvement of cough in the treatment arm. 
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Change in cough specific quality of life showed a different pattern of 
correlation. In placebo arm, the statistically significant correlations were 
seen with symptom of clearing throat; heartburn, stomach acid or 
indigestion; cough brought on by speaking or singing; and cough more 
while awake than asleep. All the correlations were negative. In treatment 
arm, correlation between change in MLCQ score and change in symptom 
severity were significant with the symptoms coughing on lying down or 
bending over, chest tightness or wheeze on coughing, heartburn, 
indigestion or stomach acid, cough with certain foods, and coughing more 
when awake than asleep. 
 
Table 4-29 Correlation of change in symptom severity to improvement in cough and change in MLCQ score 
  
Improvement in cough Change in MLCQ score 
Placebo 
(N=22) 
Treatment 
(N=18) 
Placebo 
(N=23) 
Treatment 
(N=16) 
Hoarseness ρ 0.01 -0.60 -0.3 -0.39 
P 0.979 0.008 0.159 0.131 
Clearing your throat ρ -0.24 -0.36 -0.64 -0.36 
P 0.275 0.147 0.001 0.170 
Postnasal Drip ρ -0.08 -0.4 0.07 0.08 
P 0.718 0.102 0.744 0.781 
Retching or vomiting while coughing ρ -0.34 -0.46 -0.44 -0.27 
P 0.121 0.052 0.035 0.310 
Cough on lying down or bending over ρ -0.30 -0.81 -0.14 -0.62 
P 0.176 0.000 0.53 0.010 
Chest tightness or wheeze when 
coughing 
ρ -0.07 -0.67 -0.29 -0.59 
P 0.744 0.002 0.172 0.016 
Heartburn, stomach acid or indigestion ρ -0.34 -0.59 -0.46 -0.64 
P 0.13 0.010 0.031 0.008 
Tickle or lump in throat ρ -0.2 -0.49 -0.33 -0.45 
P 0.381 0.039 0.122 0.081 
Cough with eating ρ -0.02 -0.13 0.07 -0.15 
P 0.931 0.600 0.744 0.591 
Cough with certain foods ρ 0.06 -0.46 0.21 -0.74 
P 0.811 0.052 0.33 0.001 
Cough when you get out of bed in 
morning 
ρ -0.18 -0.47 -0.21 -0.06 
P 0.415 0.048 0.343 0.821 
Cough brought on by speaking or singing ρ -0.38 -0.10 -0.52 -0.04 
P 0.082 0.686 0.012 0.87 
Coughing more when awake than asleep ρ -0.16 -0.70 -0.54 -0.64 
P 0.482 0.002 0.008 0.010 
Strange taste in your mouth ρ -0.01 -0.43 0.23 -0.23 
P 0.967 0.072 0.294 0.399 
4.10. Compliance to treatment 
Pill count on follow-up was a marker assessed for compliance to 
treatment. Median pill count was 5.50 with IQR (0-14) and was not 
- 73 - 
 
different significantly between the placebo and treatment groups (Z= -
0.884, P= 0.376).  
5. Discussion 
During this study, we for the first time enrolled patients suffering from 
HAC after ruling out other causes of cough at altitude and examined the 
effect of an anecdotally successful treatment regimen against placebo. The 
treatment regimen of salmeterol/fluticasone was been reported by 
experienced high altitude physicians in successfully treating HAC. 
5.1. Improvement in cough 
From the data of this study, we found that both placebo and the treatment 
combination of salmeterol/fluticasone improve HAC at EBC. HAC 
improved in 34 (85%) subjects at follow up independent of the study arm. 
Only 6 (15%) of the participants reported no changes in the status of 
cough at follow up. We showed that the improvement in cough at follow 
up for combination treatment of salmeterol/fluticasone was not superior to 
placebo in treatment of HAC at Everest base camp (P= 0.645).  
Nationality did not play a role in subjective reporting of improvement of 
cough at follow up (P= 0.066).  
Improvement in cough correlated well with MLCQ score at follow up in 
both arms. In both arms, the correlations were positive, showing that a 
better improvement in cough was correlated well with a higher MLCQ 
score which reflected an improvement in the quality of life. In both 
placebo arm and treatment arm, correlations were significant at the level 
0.000.  
Improvement in cough correlated significantly in both arms with change 
in MLCQ score. A higher change in MLCQ scores meant a better 
outcome with cough status. We could conclude that the self-reported 
cough severity used in this study has a good correlation with quality of 
life measurement with MLCQ. Even in absence of more objective tools, 
patient reported subjective improvement of cough is a useful tool in cough 
research. 
There was no difference between the arms in significant improvement of 
HAC at follow up (P= 0.538). The odds of significant improvement in the 
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treatment arm in comparison to placebo arm were not significant (0.865; 
[0.246, 3.050]). We concluded that even though the drug combination of 
salmeterol/fluticasone improve cough in HAC, it is not better than 
placebo in resulting in such an outcome. 
HAC is still a poorly understood phenomenon. There is good evidence 
that cough threshold is decreased at high altitude even in a controlled 
hypobaric chamber environment [29]. We know that HAC is an important 
cause of morbidity at very high altitude, but so far we do not know how to 
treat it. From earlier trials in cough treatment, we know the existence of 
physiological effect of placebo apart from true placebo effect causing 
improvement in cough[77]. During this study, comparing placebo arm 
effect with a no-treatment arm was not planned. Hence, we could not 
measure the effect size of placebo on HAC. We have shown that in both 
treatment and placebo arms, HAC improved significantly. There was an 
improvement of cough seen in 85% of participants. Patients enrolled in 
treatment arm even had a worse odds (though not statistically significant) 
in significantly improving than their counterparts in placebo arm.  
Improvement of cough by resolution of early lung edema in sub-clinical 
HAPE would be supported by the improvement of cough seen in the 
treatment arm of salmeterol/fluticasone combination. This was a main 
argument for the anecdotal success of the drug combination. Though we 
saw a big improvement in cough in treatment arm, the effect of placebo 
was the same. We cannot make a case for sub-clinical HAPE through our 
results. 
Improvement seen in such a high percentage of cough patients 
irrespective of the treatment arm can lead to inference that maybe HAC is 
a self-limiting condition. Previous studies have shown in chamber studies 
and at altitude that the threshold to cough is lowered in hypobaric hypoxia 
and subjects suffered from dryness in throat and irritating cough and the 
cough threshold levels returned to normal values on descent to lower 
altitude [29, 78]. Natural course of HAC is not described in the literature, 
with most information being anecdotal; and we cannot say exactly how 
natural history of HAC has affected our trial results. HAC is typically a 
self-limiting condition when exposure to the mountains is removed and 
climbers return to lower altitudes. Anecdotally, and from personal 
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experiences, patients of HAC complain of cough lasting weeks to months 
after returning to native altitudes, though the severity decreases with time.  
There are no previous treatment- studies in HAC to compare the study 
results with. The other cough treatment studies are from low altitude, and 
comparison with these is possible as there as big differences in the tools 
used, as well as there are significant differences in respiratory physiology 
at high altitude and pathophysiology of HAC.  
5.2. Quality of life measurement 
We showed during this study that the MLCQ was a reliable questionnaire 
that can be employed to assess HAC at high altitude settings (Cronbach's 
alpha at baseline: 0.816, at follow up: 0.906).There was no difference in 
response between the Nepalese and non-Nepalese nationalities, thus 
making it useful for assessing quality of life in across nationalities at 
EBC.  
We did not find any difference on comparing placebo and treatment arms 
in terms of MLCQ score at follow up, or the change of MLCQ score from 
baseline. However, comparisons in each arm between baseline and follow 
up scores revealed a significant difference in each arm. Difference 
between MLCQ score was follow up and MLCQ score at baseline was 
positive, indicating that quality of life had increased in both arms after 
intervention. On analyzing differences in domain scores, we found 
significant differences in all domains in the placebo arm whereas 
statistical difference was found only in physical domain in the treatment 
arm.  
5.3. Clinical variables 
Heart rate (pulse rate) increases on acute exposure to hypoxia [79, 80]. 
But on prolonged exposure to altitudes of up to 6000 meters, pulse rate 
returns to normal values [80]. All the study participants had spent at least 
2 weeks at high altitude before being enrolled in the study. Both at 
baseline and follow up, mean pulse rate in the study population was 
within normal range for an adult which is 60-100 per minute. In the study 
participants, pulse rate showed contrasting changes in placebo and 
treatment arms. Mean pulse rates at follow up decreased in placebo arm 
compared to baseline mean pulse rate measurements, whereas mean pulse 
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rate measurements in the treatment group increased at follow up in 
comparison to baseline values. Though these changes are not significant, 
this might be due to the salmeterol component of the combination 
treatment [67].  
Oxygen saturation decreases with altitude[81]. Our study participants 
showed lowered levels of oxygen saturation both at baseline and follow 
up. The percentage SpO2 measured in our study was not significantly 
different from measurements in earlier studies at high altitude [23, 82-84]. 
We did not find a significant change in either of the intervention arms in 
SpO2 at follow up.  
Blood pressures rise on exposure to high altitude and this increase is 
related to hypoxic ventilator response at altitude [79]. Our data showed a 
raised SBP and DBP at baseline that fell under the category of 
'prehypertension' compared to optimum sea level blood pressure values 
[85]. At high altitude, there is no established literature on the nature of 
rise in systemic blood pressure and there are big inter-individual 
differences. Treatment of all symptomatic hypertension cases and, if 
asymptomatic, cases with more than 200/120 mmHg is recommended 
[86].  None of the participants had such levels of blood pressure in our 
study. SBP and DBP measurements were not significantly different than 
observed in other studies at high altitude [82, 83, 87]. At follow up, we 
found that mean DBP in treatment arm was lower than mean DBP at 
baseline, whereas in placebo mean DBP at follow up was higher than 
mean DBP at baseline. Though these changes were not significant, a 
reason for the differing directions of change could be the salmeterol 
component of the combination treatment [67]. 
PEF values in placebo during follow up were significantly higher than at 
enrollment. There was an improvement in PEF seen also in the treatment 
group at follow up in comparison to baseline measurements but the 
difference was not significant. Studies on PEF at high altitude have shown 
a significant increase in comparison to sea level measurements [23, 29].  
The improvement in PEF is seen together with the improvement in cough 
status and MLCQ score at follow up but we cannot with certainty explain 
the significant increase in placebo PEF values since the measurements 
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were carried out at the same altitude of EBC in acclimatized climbers. We 
saw a significant increase in FEV1 in total population at follow up on 
comparison to baseline measurements but the significance vanishes on 
analysis of individual arms.  
Earlier studies looking at the pulmonary function tests have looked 
primarily at FVC values and shown that it decreases with altitude. 
However, some studies have looked at PEF and FEV1 at altitude. These 
studies have compared differences of the pulmonary functions from sea-
level to altitude values. With such comparisons, earlier studies have also 
ruled out the presence of bronchoconstriction at altitude with the help of 
beta agonists and oxygen supplementation [23, 29, 69]. PEF and FEV1 
mean values, both at baseline and follow up are higher than values 
defining bronchospasm in a 34 year-old, 170 cm tall Caucasian male [75]. 
Values for PEF and FEV1 in Indian population are smaller [76, 88], and 
although one study has found higher FEV1 values in the Nepalese 
Sherpas in comparison with the European coal and steel (EC&S) FEV1 
and FVC data [89], a national standard for pulmonary function does not 
exist in Nepal.  
Our measurements were all carried out at altitude, on participants who 
were exposed to effects of altitude for at least 2 weeks, and suffering from 
HAC. We did not measure FVC during this study. Earlier studies at high 
altitude have shown that FVC reduces significantly at altitude from sea 
level values but there is no change in FEV1 and PEF rather increases at 
altitude [29].  
We have shown the absence of effect of salmeterol/fluticasone 
combination treatment in pulmonary function in participants with HAC in 
comparison to placebo. In our data, PEF in placebo has increased 
significantly at follow up from baseline values, but not in treatment arm. 
FEV1 has not increased significantly at all in both arms. There is good 
evidence that in chronic lung disease, this combination improves FEV1 
and PEF [90].In asthma, the drug combination is recommended as anti-
inflammatory properties of fluticasone enhances the bronchodilator effect 
of salmeterol and the beta-agonist action of salmeterol enhances the action 
of fluticasone through the gluco-corticoid receptors; resulting in a better 
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overall control of symptoms and improvement of lung function [91]. If 
bronchoconstriction related to hyperventilation or hypocapnia was 
present, salmeterol would reverse the condition [56]. In present study, 
failure of improvement in lung function parameters in the treatment arm 
makes it difficult to argue for the case of broncho-constriction in being a 
causal factor for HAC. 
5.4. Symptom severity checklist 
Post-nasal drip and gastro-esophageal reflux are important causes of 
cough in low and high altitude [16, 92]. In the present study, the relation 
of some of the symptoms related to GERD and PND to the improvement 
of cough and to the change in MLCQ score from baseline values was 
examined. Other symptoms used to relate the severity of cough were also 
examined and similar associations studied. For both types of symptoms, 
we also calculated the change in the severity between baseline 
measurements and follow up and examined the association of the change 
to the improvement of cough and the change in quality of life. At follow 
up, irrespective of the study arm, the symptom severity decreased in 
participants with improvement in cough. We did not find correlation 
between any symptom and cough improvement in placebo arm at follow 
up. The same was true for change in symptom severity from baseline.  
In treatment arm, we saw significant negative correlation of improvement 
in cough with change in severity of symptoms related to GERD/PND 
(hoarseness, cough on lying down or bending over, heartburn, stomach 
acid or indigestion, tickle or lump in throat), and symptoms related to 
cough severity (chest tightness or wheeze when coughing, cough when 
you get out of bed in morning and coughing more when awake than 
asleep). With these symptoms, a greater reduction in the symptom 
severity correlated well with better level of improvement in cough.  
Similarly, not all symptoms were related with a change in quality of life at 
follow up. A change in symptom severity of heartburn, stomach acid or 
indigestion (symptom of GERD), and coughing more when awake than 
asleep (symptom of severe cough) were significantly related to the change 
in MLCQ score in both arms. Clearing your throat (symptom of GERD), 
retching or vomiting while coughing, and cough brought on by speaking 
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or singing (symptoms of severe cough) were correlated in the placebo arm 
to the change in MLCQ score. Cough on lying down or bending over 
(symptom of GERD and severe cough), chest tightness or wheeze when 
coughing, and cough with certain foods (symptoms of severe cough) were 
correlated to change in MLCQ score in the treatment arm. All these 
correlations were negative; a greater reduction in the severity of 
symptoms was associated with a greater increment in the quality of life 
score. 
Most of the symptoms regressed at follow up in both study arms. 
Decrease in symptoms of severe cough can be attributed directly to the 
improvement in cough itself. Decrease in severity of symptoms of GERD 
is difficult to understand, since the treatment regimen used does not have 
an effect in reducing acid reflux. Some symptoms of GERD are also 
common to PND symptoms; hoarseness, clearing throat, and tickle in 
throat. A reduction in severity of these symptoms could have been 
brought about by fluticasone. 
5.5. Relation of HAC to exercise 
At baseline, we saw a difference between placebo and treatment arms in 
the relation of HAC to exercise. A greater proportion in the placebo 
responded that HAC was not related to exercise whereas in treatment 
group, greater percentage of participants responded that exercise makes 
HAC worse. This difference vanished at follow up and in both arms, most 
of the participants responded that the cough was not related to exercise. 
However, there were still 1 in 3 participants at follow up (34.15%) who 
reported that HAC was made worse by exercise.  
5.5. Altitude of HAC occurrence 
Altitude-related cough has been explained to occur in two forms by 
researchers earlier. A type of cough occurring at altitudes below 5000 
meters probably due to trauma to respiratory mucosa and a cough 
occurring above 5000-6000 meters altitude that might me correlated with 
sub-clinical HAPE has been proposed. The cough from lower altitude 
persists on descent while the cough developed at the higher altitudes 
improve on descent [29]. This is the first time we have collected 
information in the altitude where the HAC occurs for the first time in 
patients. 
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In this study, on reporting the altitude where their cough started, most of 
the climbers participating reported the altitude range 5000-5999 meters 
which includes the EBC. Second most common altitude of occurrence of 
HAC was 4000-4999 meters. These responses were preserved on 
analyzing the study arms or the nationalities of participants responding. 
HAC, linked with sub-clinical pulmonary edema by earlier researchers, is 
thought to develop above 5000-6000 meters, which more or less agrees to 
our findings in the study.  We still saw a number of participants 
developing cough at lower altitudes. During this study, we excluded 
cough patients who reported symptoms of infection prior to the 
development of cough. 
5.6. Characterization of HAC 
Causation of cough is multifactorial. The nature and etiology of cough at 
altitude is not defined and may cover a number of conditions and 
etiologies [29]. During the inception of this study, a consensus was 
developed among high altitude experts and experienced high altitude 
physicians that HAC is a unique condition and was defined accordingly. 
From the data gathered in the study, we could add some more 
characteristics regarding HAC. 
With the data at baseline, we can see that a patient of HAC is typically a 
young climber (mean age 34.42 years), predominantly male (88.46%), 
without allergies, not using acetazolamide, with a fast ascent profile 
(mean 6.1 nights from 2800 meters to 5300 meters), without chronic 
illnesses. HAC patients also had their pulse rate and blood pressure within 
normal reference range for the altitude of study. In maintaining with the 
initial definition, patients diagnosed with HAC by high altitude 
physicians, who agreed to volunteer in the study, had a peripheral oxygen 
saturation of 83.06±3.84 percentage. We could not, in this study, explain 
lung function changes in HAC patients between low and high altitude.  
5.7. Differences between Nepalese and non-Nepalese climbers 
In EBC, we have shown that the Nepalese climbers with HAC are 
younger than their non-Nepalese counterparts, and took much smaller 
amount of time to reach the EBC altitude of 5300 meters from point of 
entry into the Everest region, Lukla (2800 meters). Having the symptom 
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of breathlessness was distributed with significant difference between the 
nationalities. 
Nepalese climbers had lower mean oxygen saturation than the non-
Nepalese climbers. Mean pulse rate among Nepalese climbers was higher 
than non-Nepalese climbers, though the differences were not statistically 
significant. Sherpa climbers, adapted to live in high altitude, are 
descended from Tibetan population. There is evidence that Tibetan high 
altitude population suffers from lesser altitude stress and has a lower level 
of oxygen saturation than high altitude populations of other regions of the 
world [93]. 
We also found significant differences in PEF between Nepalese and non-
Nepalese participants at EBC. Nepalese climbers had a significantly lower 
PEF than non-Nepalese participants of the population. This can be 
explained by the stature difference of Nepalese climbers to the non-
Nepalese climbers, as is it known that the lung volume which is a function 
of thoracic dimensions and hence stature, affects PEF [94, 95].  
By looking at the baseline characteristics, we can conclude that Nepalese 
and non-Nepalese participants are different at high altitude. Nepalese 
population is altitude adapted population, working at high altitude for 
many years, while the non-Nepalese participants were climbers but not 
adapted chronically to very high altitudes of the Himalayas. Without 
proper randomization, the difference in features of these two groups of 
participants could have had an effect on the results. But we showed that 
the nationality of participants was well distributed among the study arms 
and the chances that nationality of participants affecting the results was 
nullified.  
In FEV1, there was a significant difference between male and female 
climbers at EBC. Though the number of female climbers was low in the 
study, FEV1 measurements are affected among many other factors, by 
gender differences [95] which could have resulted in the study 
conclusions. 
5.8. Implications of the study 
HAC is still a poorly understood condition troubling not only high 
mountain climbers but all sojourners to high altitude destinations around 
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the world. It is a common problem, without a proven treatment, frequently 
resulting in failed expeditions and decreased quality of life in patients.  
Though common, we do not yet know the complete natural history of 
HAC, apart from anecdotal reports and further work is needed to 
understand this condition. 
HAC is a diagnosis of exclusion, but it is extremely difficult at high 
altitude environment to be able to rule out every other cause of cough. 
Cough at altitude does not have a uniform nomenclature. It is common for 
HAC to be labeled as some other kind of cough. There is a necessity to 
use a uniform diagnosis standard to be used at various high altitude sites 
around the world. We recommend the use of the definition of HAC used 
in this study for diagnosis. Hence, a persistent, sometimes paroxysmal 
cough that disturbs sleep or daily activity or both for more than 1 day in 
high altitude environment, dry or productive in nature, and not associated 
with fever, chills, and shortness of breath or desaturation and without 
significant clinical changes in evaluation of the respiratory and 
cardiovascular system can be labeled as HAC. Absence of broncho-
constriction in lung function test can be used as an additional marker, if 
available. We cannot support the theory of the role of bronchoconstriction 
playing in HAC from the results of the present study.   
There is clearly a need to study other treatment options in HAC. 
Additionally, there is a need to study the effects of a placebo treatment 
with comparisons to a no treatment arm in future studies. We cannot 
overlook the placebo effect in HAC and future studies must make power 
and sample calculations taking into account this fact. 
Through the results of this study, we have concluded that improvement in 
cough results in better quality of life and as such, it is important to treat.  
We have shown that HAC improves with intervention, but no evidence 
could be shown for treatment regimen we used. Though we cannot 
support the use of salmeterol/fluticasone combination treatment in HAC, 
there may be other types of cough at altitude developing due to causes 
that may respond to this treatment regimen. 
Sub-clinical HAPE being a probable cause for HAC was a reason for 
choosing the treatment combination that has evidence in prevention of 
HAPE. Though physiologically sound, the theory of sub-clinical HAPE as 
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a causal factor for HAC is still not proved. The study findings showed that 
treatment combination with salmeterol, which is a drug for HAPE 
prevention and acts by enhancing fluid clearance from lungs, was not 
more effective than placebo. Further studies as to the establishment of 
sub-clinical HAPE as a causal factor of HAC and treatment options that 
enhance fluid clearance from lungs in sub-clinical HAPE are needed to 
support this theory.   
Though improvement in the symptoms of GERD/PND has correlated well 
with improvement in cough and quality of life, further research is needed 
before a causal relation can be established. Nasoendoscopy and 
esophageal pH monitoring in patients with cough could provide evidence 
for GERD/PND. On assessing symptom severities, it would also be 
helpful in future studies on HAC to see a relation with the reflux severity 
index (RSI), which is a well validated measure of  GERD symptom 
severity [64]. Of this index, many but not all elements were parts of the 
symptom checklist used during this study. 
5.9. Limitations of study 
This study presented some unique limitations to deal with. The study was 
conducted among Himalayan mountaineers at EBC, and the follow up 
times for the participants could not be controlled. The terrain, weather 
high on the mountain and team climbing schedule led to the modification 
of two follow up points planned initially at week 1 and week 2. Follow up 
data, finally, was collected at a single point between weeks 1 and 2.  
Most climbers with severe symptomatic cough did not participate, citing 
their plan to use the known salmeterol/fluticasone inhaler rather than risk 
being placed in a placebo group. The drug combination features regularly 
in expedition medical kits to very high altitude based on recommendations 
from high altitude medicine experts.  Though this is the first study to 
gather data on the salmeterol fluticasone combination treatment, it is 
commonly used in various high altitude areas around the world. This also 
resulted in 2 participants in changing from the treatment regimen to the 
commercial drug combination, thus dropping out of the study.  
Forced vital capacity (FVC) was not recorded during the spirometry 
recordings and the standard data for the local population is not available, 
FEV1 and PEF can only be analyzed against standard data from other 
regions of the world. 
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MLCQ has not been used in the mountaineering population previous to 
this study, hence the results generated from the MLCQ in this study, 
though strong, have not been verified in other studies yet.  
Despite the challenges, this is the only randomized placebo-controlled 
double blind study to date in the treatment of HAC done at a high altitude 
site. 
6. Conclusion 
There is not enough pathophysiological evidence that the HAC is a direct 
result of sub-clinical HAPE [18, 29] nor is there enough evidence of 
inflammation in the airways in HAC. In current study, as treatment 
combination fluticasone and salmeterol failed to show better effect than 
placebo, we cannot prove the case for sub-clinical HAPE or argue the 
case of inflammation and bronchoconstriction in HAC although with the 
results of this study, we cannot rule out these causes with certainty. Our 
study points to the need of more research into the unique problem of 
HAC.  
There is a distinct lack of literature in HAC, starting from the clinical 
history and progression of the disease, most work being done is based on 
experience. There are few studies in the pathophysiology of HAC done in 
hypobaric chambers. Further studies should address the natural history of 
HAC. Direct visualization of the upper respiratory tract with endoscopic 
procedures could give invaluable insight in the causation of HAC. This 
can be followed by furthering of the pathophysiology studies of HAC, 
including broncho-alveolar lavage studies to look for markers of 
inflammation. Treatment studies should be continued to gather evidence 
for the best treatment for HAC, hence treatment studies also help to 
accept or reject pathophysiological models. Candidate treatment options 
in HAC are established antitussives like dextromethorphan and codeine. 
There is some evidence that acetazolamide inhibits cough reflex, data on 
HAC is still to be gathered.  Studies to establish causation (hypotheses 
listed in the introduction section) would also point to further treatment 
trials. 
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More emphasis in the prevention of HAC should be the goal for high 
altitude climbing practices. A good acclimatization profile, along with 
proper hydration and use of moisture retaining buff or balaclavas do help. 
Hard candies and general cough syrup can provide a sense of relief even 
though they do not cure HAC. In case of severe cough, descent to a lower 
altitude could be necessary. In case of well acclimatized climbers, 
centrally acting antitussives can be tried under supervision of medical 
personnel acquainted with high altitude medicine. Additionally, based on 
the results of our study, we cannot support the recommendation to the use 
of combination treatment of salmeterol/fluticasone in the treatment of 
HAC. 
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Appendix 


1 
Modified Leicester Cough Questionnaire 
                           Study # ___________ 
 
                                
 
High Altitude Cough (Before Intervention)  
 
Cough can be a major problem for people travelling to altitude. It can ruin your climb by limiting exercise, 
preventing sleep or even causing rib fractures. The questionnaire is completely anonymous and you cannot be 
identified in anyway from it. Should you agree to complete the questionnaire, please fill it in as accurately and as 
honestly as possible. Thank you for your help! 
 
Age: ……   M / F   Nationality: ...…....…………   Independent/ Commercial group (please circle) 
 
# Nights from Lukla to EBC: .........    # days at EBC or above: ____     
 
______________________________________________________________________________ 
 
Do you have any long term illnesses or take any regular tablets or medicines prescribed by a doctor?  
 
Please give brief details: 
……………………………….……………….………………………………………………………………… 
___________________________________________________________________________________________ 
 
Are you taking Diamox during this trip?  Yes / No     If yes, dose: ……… 
 
Are you taking any other medications? Yes/No  If yes, please list: 
Do you have any allergies?    Yes/No  If yes, please list:  
 
 
During your time on the trek in or in EBC or above, have you experienced Breathlessness (worse than previous 
altitude experience or compared with others in your group)? (Please circle most appropriate response)  
 None / Mild / Moderate / Severe/ Incapacitating   
 
Please CIRCLE the response that best applies to you: 
 
a) Have you been troubled by a cough during your time in EBC or above?  
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
b) Have you had chest or stomach pains as a result of your cough? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
c) Have you been tired because of your cough? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
d) Have you been bothered by sputum (phlegm) production when you cough? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
e) Have you felt in control of your cough? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
f) How often have you felt embarrassed by your coughing? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the t 
 
g) My cough has made me feel anxious: 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time  
 
h) My cough has interfered with my ability to exercise, or other daily tasks: 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
i) I feel that my cough interferes with the overall enjoyment of my climb: 
1  2 3 4 5 6   7  
2 
Modified Leicester Cough Questionnaire 
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
j) Exposure to smoke or fumes has made me cough: 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
k) My cough has disturbed my sleep: 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time Not at all 
 
l) How many times a day have you had coughing bouts? 
1  2 3 4 5 6   7  
All of the time  Most times during Several times during Sometimes during Occasionally  Rarely   Never 
(continuously) the day the day the day through the day 
 
m) My cough has made me feel frustrated: 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
n) Have you suffered from a hoarse voice as a result of your cough? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
o) With the cough have you had a lot of energy? 
1  2 3 4 5 6   7  
None of the time  Hardly any of A little of the time Some of the time A good bit of    Most of the time   All of the time 
                            the time the time     
   
p) Have you worried that your cough may indicate serious illness? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
q) Have you been concerned that other people think something is wrong with you, because of your cough? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
r) My cough has interrupted conversation: 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly at all   Not at all 
 
s) I feel that my cough has annoyed my fellow climbers or tent partner: 
1  2 3 4 5 6   7  
Every time I   Most times when Several times when Sometimes when Occasionally    Rarely   Never  
cough I cough I cough I cough when I cough 
 
t) My cough seems to be related to exercise: 
1 2  3 
Only brought on  Made worse by Not related to exercise 
by exercise exercise 
 
u) At what altitude did your cough begin?    
1 2 3 4 5 6 
1000 – 1999 m  2000 – 2999 m  3000 – 3999 m  4000 – 4999 m  5000 -5999 m  Above 6000 m  
 
____________________________________________________________________________________________________________ 
 
Please CIRCLE the response that best applies to you: 
 
During your time at EBC and climb, how, if at all, did the following problems affect you?  (0 = no problem and 5 = severe or frequent problem): 
 
a) Hoarseness or a problem with your voice:   0 1 2 3 4 5  
  
b) Clearing your throat:    0 1 2 3 4 5  
 
c) The feeling of something dripping down the back of your nose or throat: 0 1 2 3 4 5  
  
d) Retching of vomiting when you cough:   0 1 2 3 4 5  
 
e) Cough on first lying down or bending over:   0 1 2 3 4 5  
 
f) Chest tightness of wheeze when coughing:   0 1 2 3 4 5  
 
g) Heartburn, indigestion or stomach acid coming up:   0 1 2 3 4 5 
    If you take medications for this, please score 5  
 
h) A tickle in your throat, or a lump in your throat:   0 1 2 3 4 5  
 
i) Cough with eating (during or soon after meals):   0 1 2 3 4 5 
  
j) Cough with certain foods:    0 1 2 3 4 5  
3 
Modified Leicester Cough Questionnaire 
 
k) Cough when you get out of bed in a morning:   0 1 2 3 4 5  
 
l) Cough brought on by speaking or singing:   0 1 2 3 4 5  
 
m) Coughing more when awake than asleep:   0 1 2 3 4 5  
 
n) A strange taste in your mouth:    0 1 2 3 4 5 
 
 
 
THANK YOU FOR THE TIME YOU HAVE TAKEN TO COMPLETE THIS QUESTIONNAIRE 
 
 
 
The following to be filled out by research staff 
 
 
OXYGEN Saturation: _____%   Pulse: ______   Blood Pressure: ____/____   
Peak Flow: ________  FEV1: _______ 
 
 
 
4 
Modified Leicester Cough Questionnaire 
 
                                                                                                                                                                 Study # ___________ 
 
 
High Altitude Cough (After Intervention)   
 
 
After the administration of the inhaled medicines given to you at EBC, in general how is your cough now 
compared to beginning of treatment?  (Please circle most appropriate response)     
                         
1   2   3      4   5 
No Improvement Improved a bit   Improved moderately    Improved greatly Completely resolved  
No cough! 
Highest camp reached? 
 
Please CIRCLE the response that best applies to you: 
 
a) Have you been troubled by a cough during your time in EBC or above?  
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
b) Have you had chest or stomach pains as a result of your cough? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
c) Have you been tired because of your cough? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
d) Have you been bothered by sputum (phlegm) production when you cough? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
e) Have you felt in control of your cough? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
f) How often have you felt embarrassed by your coughing? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the t 
 
g) My cough has made me feel anxious: 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time  
 
h) My cough has interfered with my ability to exercise, or other daily tasks: 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
i) I feel that my cough interferes with the overall enjoyment of my climb: 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
j) Exposure to smoke or fumes has made me cough: 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
k) My cough has disturbed my sleep: 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time Not at all 
 
l) How many times a day have you had coughing bouts? 
1  2 3 4 5 6   7  
All of the time  Most times during Several times during Sometimes during Occasionally  Rarely   Never 
(continuously) the day the day the day through the day 
 
m) My cough has made me feel frustrated: 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
n) Have you suffered from a hoarse voice as a result of your cough? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
 
 
 
 
5 
Modified Leicester Cough Questionnaire 
o) With the cough have you had a lot of energy? 
1  2 3 4 5 6   7  
None of the time  Hardly any of A little of the time Some of the time A good bit of    Most of the time   All of the time 
                            the time the time     
   
p) Have you worried that your cough may indicate serious illness? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
q) Have you been concerned that other people think something is wrong with you, because of your cough? 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly any of the time None of the time 
 
r) My cough has interrupted conversation: 
1  2 3 4 5 6   7  
All of the time  Most of the time A good bit of the time Some of the time A little of the time   Hardly at all   Not at all 
 
s) I feel that my cough has annoyed my fellow climbers or tent partner: 
1  2 3 4 5 6   7  
Every time I   Most times when Several times when Sometimes when Occasionally    Rarely   Never  
cough I cough I cough I cough when I cough 
 
t) My cough seems to be related to exercise: 
1 2  3 
Only brought on  Made worse by Not related to exercise 
by exercise exercise 
 
 
____________________________________________________________________________________________________________ 
 
Please CIRCLE the response that best applies to you: 
 
After using the inhaled medcines, did the following problems affect you?  (0 = no problem and 5 = severe or frequent problem): 
 
a) Hoarseness or a problem with your voice:  0 1 2 3 4 5  
  
b) Clearing your throat:   0 1 2 3 4 5  
 
c) The feeling of something dripping down the back of your nose or throat: 0 1 2 3 4 5  
  
d) Retching of vomiting when you cough:  0 1 2 3 4 5  
 
e) Cough on first lying down or bending over:  0 1 2 3 4 5  
 
f) Chest tightness of wheeze when coughing:  0 1 2 3 4 5  
 
g) Heartburn, indigestion or stomach acid coming up:  0 1 2 3 4 5 
    If you take medications for this, please score 5  
 
h) A tickle in your throat, or a lump in your throat:  0 1 2 3 4 5  
 
i) Cough with eating (during or soon after meals):  0 1 2 3 4 5 
  
j) Cough with certain foods:   0 1 2 3 4 5  
 
k) Cough when you get out of bed in a morning:  0 1 2 3 4 5  
 
l) Cough brought on by speaking or singing:  0 1 2 3 4 5  
 
m) Coughing more when awake than asleep:  0 1 2 3 4 5  
 
n) A strange taste in your mouth:   0 1 2 3 4 5 
 
 
THANK YOU FOR THE TIME YOU HAVE TAKEN TO COMPLETE THIS QUESTIONNAIRE 
 
 
 
The following to be filled out by research staff 
 
 
OXYGEN Saturation: _____%   Pulse: ______   Blood Pressure: ____/____   
Peak Flow: ________  FEV1: _______ 
 
 
1 
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CONSENT FORM  
  
High altitude Cough 
 
 
Principal Investigator: Buddha Basnyat MD - Director, Himalayan Rescue Association. 
Nepal International Clinic - GPO BOX 3596, Lal Durbar Marg 47, Kathmandu, Nepal  
Ph# 977-1-434 642,435 357 
  
 
I have read the Patient Information Sheet and understand what will happen in the study.  I 
understand that my participation in this study is completely voluntary and that I may leave the 
study at any time.  There will be no consequences of deciding not to be in the study.  All 
information about me will remain strictly confidential.  I can contact the principal investigator at 
any time if I have concerns or questions about being in the study.  His information is at the top 
of this form.  
 
My signature below indicates that I have read and understand the procedures described in the 
Patient Information Form and give my informed and voluntary consent to participate in this 
study.  A copy of this form will be given to me for my records. 
 
 
 
Participant Name:_________________________________ 
 
 
 
Signed:   ____________________________________    Date:______________   
 
 
 
 
Study Staff Name:____________________________________ 
 
 
 
Signed:____________________________________    Date:______________   
 
 
1 
Patient Information Sheet – Cough at high altitude V.1 25JUN09 
Participant Information Sheet 
High altitude cough 
High altitude cough (HAC), also known as Khumbu cough has been the number one diagnosis for the 
last 7 years amongst climbers in the Everest Base Camp clinic in Nepal. Cough can be very 
debilitating at high altitude and can be severe enough to cause a rib fracture. Many factors seem to 
be involved in causing this cough. At the Everest Base Camp anecdotally over the years the doctors 
have noticed that an inhaled combination of Salmeterol and Fluticasone has been very effective in 
the treatment of HAC, but this has never been proven in scientific study.  
The main purpose of this research study is to find out if inhaled Salmeterol and Fluticasone will be 
effective for the treatment of HAC in high altitude climbers. Both Salmeterol and Fluticasone are 
commonly used drugs for asthma. 
This is a randomized trial (RCT); half of the participants receive a placebo and others will receive the 
study drug. Study groups will be randomly assigned by a computer generated list and neither the 
participant nor the study administrator will know who received drug or placebo, as this is kept in a 
secret code, which can be broken by the doctors not associated with the study.  RCTs are the most 
scientific way to determine if drugs (Salmeterol\Fluticasone in this case) work or not for the stated 
purpose.   
All drugs have side effects. The inhaled combination of Salmeterol and Fluticasone is generally 
considered safe. There may be some coughing with the initial puff in some participants. Some may 
experience mild throat irritation, palpitations and mild headache. Some participants may have 
hoarseness and temporary change in voice. Sometimes oral thrush can be a problem and gargling 
the throat with water after inhalation will help avoid this.  A great advantage of these drugs is that 
they work locally in the lungs and very little is absorbed in the blood stream, so side effects are 
uncommon.    
Benefits for taking part in this study will include specialized counselling about methods of reducing 
risk of high altitude cough and two free medical evaluations.  We are happy to share the results of 
the study with you if you would like to leave your contact information with the study staff.  All 
information will remain strictly confidential and you are allowed to leave the study at any time if you 
wish.  
Principal Investigator: Buddha Basnyat MD - Director, Himalayan Rescue Association. 
Nepal International Clinic - GPO BOX 3596, Lal Durbar Marg 47, Kathmandu, Nepal  
Ph# 977-1-4434 642, 4435 357 
 
Oxford Tropical Research Ethics Committee ( OXTREC), University of Oxford.  
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